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A PROSPECTIVE STUDY OF CORRELATION BETWEEN SERUM 
URIC ACID AND DYSLIPEDEMIA IN ESSENTIAL HYPERTENSION 
ABSTRACT 
BACK GROUND: 
     The association of serum uric acid with various cardiovascular risk factors 
have led to the debate that whether serum uric acid can be an independent risk 
factor in essential hypertension. Hence we carry out a study to examine the 
possibility of hyperuricemia in hypertension, to see if there is a relationship 
between the serum uric acid levels and hypertension. Hypertriglyceridemia, 
hypercholesterolemia, raised LDL, raised VLDL and a decreased HDL is seen 
in Essential hypertensives. So we examine the possibility of occurrence of 
dyslipedemia with respect to essential hypertension, in comparison with 
normotensive. Uric acid levels tend to rise with individual rise in any one of 
lipid parameter in hypertensive cases, in comparison to normotensives.so we 
evaluate the correlation of serum uric acid and dyslipedemia in essential 
hypertensive in comparison to normotensive. As the age increases in 
hypertensives, dyslipidaemia and hyperuricemia increase together, indicating 
uric acid as a risk factor for hypertension and its complication .The 
complications of hypertension like CCF, heart failure occur more due to 
endothelial dysfunction due to dyslipedemia and raised serum uric acid. Thus, 
the predilection of correlation between serum uric acid and dyslipedemia in 
essential hypertension will help in better management of essential hypertension 
and thereby preventing associated morbidities and mortalities. 
AIMS OF THE STUDY: 
1. To measure the fasting serum uric acid levels in essential hypertensive 
individuals aged between 35 to 65 years and in healthy individuals aged 
between 35 to 65 years. 
2. To measure the fasting serum levels of lipid parameters triglycerides, 
total cholesterol, LDL, VLDL and HDL in essential hypertensive 
individuals and healthy individuals aged between 35 to 65 years 
3. To analyse the possibility of correlation existing between fasting serum 
uric acid levels and fasting serum lipid parameters. 
 
METHODS: A Case control study consisting of 30 controls, who are healthy 
individuals in the age group of 35 to 65 years, with blood pressure  of <140/90 
mmhg and 30 hypertensive cases who are individuals in the age group of 35 to 
65 years with blood pressure of >140/90mmhg is undertaken to study the 
relationship between serum uric acid and lipid parameters in essential 
hypertension in comparison to normotensive. The current study is done In 
Tiruneveli Medical College, Department of Medicine from our inpatient and 
outpatient departments from August 2013 to August 2014. Diabetes mellitus, 
ischemic heart disease, renal disease, jaundice, chronic liver disease, familial 
hyperlipidemia, patients on lipid lowering drugs, smoking, alcoholics, obese 
individuals and gout patients are excluded from the study population by history 
and physical examination. All the study population are undergone physical 
examination and their fasting serum uric acid and serum lipid profile taken for 
analysis. The information collected regarding all the selected cases were 
recorded in a Master Chart. The range, frequencies, percentages, means, 
standard deviations, chi square, ‘t’ value and  'p'  values were calculated. 
Student’s ‘t’  test was used to test the significance of difference between 
quantitative variables .Yate’s and Fisher’s chi square tests for qualitative 
variables. A 'p' value less than 0.05 is taken to denote significant relationship. 
RESULTS:  Blood pressure elevation is observed as the age group increases. 
As age increases, a rise in blood pressure elevation is observed. The level of 
blood pressure rise is observed more in 55-65 year age group. Also more 
number of hypertensives  are observed in 55-65 age group. An elevated level of 
triglycerides, LDL, VLDL and decreased level of HDL is observed more in 
hypertensive group (P <0.001significant). About 24 out of 30 cases in the 
hypertensive group has observed to have dyslipidemia ,either as total increase in 
all  lipid parameters or increase in any one of the  lipid parameter ,excluding 
HDL. In control population only few of the individuals have dyslipidemia, most 
of the control population do not have any lipid abnormality. Only 4 of 30 have 
increased triglycerides and 2 of them have increased cholesterol levels. So, 
about 80% of hypertensive population have dyslipidemia. In control population, 
only 20% have dyslipidemia and they too have only increased triglyceride 
levels. Also the rise in lipid parameters is more with age group, more seen in 
55-65 years age group and the elevation also increases with increase in blood 
pressure. Uric acid elevation is seen in most of the individuals in hypertensive 
group (P <0.0001- significant). About 25 of 30 people have elevation of serum 
uric acid and its elevation is directly proportional to rise in blood pressure. Uric 
acid level is not elevated in control group. The dyslipidemia is associated with 
elevation of serum uric acid in hypertensive group, where as in control group 
dyslipedemia is not associated with elevation of serum uric acid.  
CONCLUSION: Dyslipidemia is seen in essential hypertensives. Elevation of 
triglycerides, rise in total cholesterol, raised LDL and raised VLDL and a 
decrease in HDL is observed in essential hypertensives. Elevation of serum uric 
acid level is seen in essential hypertensives. Both dyslipidaemia and 
hyperuricemia observed to be elevated with increase in age in essential 
hypertensives. In normotensives, few have elevated triglyceride levels and 
elevated total cholesterol levels. Though hypertriglyceridemia increases as age 
increases, it is not associated with hyperuricemia. This concludes that 
dyslipidemia is correlated to hyperuricemia in essential hypertensives and not in 
normotensives. 
KEY WORDS: serum uric acid, dyslipedemia, essential hypertension, 
correlation,  
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INTRODUCTION 
 
Hypertension is one among the most vital non communicable diseases 
contributing to global burden of morbidity and mortality and one of the vital 
cause leading on to death. Hypertension has been associated with increased 
incidence of cardiovascular pathology, which includes coronary artery heart 
disease, heart failure, ischemic and haemorrhagic stroke, renal disease, and 
peripheral arterial disease. It has been seem to be linked with cardiovascular 
risk factors, and so the risk amount increases with the total weight of risk 
factors.  
 Even though it is present worldwide, the major toll occurs in the 
developing nations rather than developed nations due to unawareness and 
inadequate treatment
1
. Proper educational strategies will help to manage the 
epidemics of hypertension
2
. 
Even treatment of hypertension seems to reduce the risks of 
cardiovascular and renal pathology, majority of the hypertensive group are 
not treated sufficiently, due to unawareness of the problem
4
.Among 
hypertensive, renal disease is an important complication especially with 
more severe Hypertension
5
. 
The Asia Pacific cohort studies collaboration clearly demonstrated the 
log linear relationship of  blood pressure with ischemic & haemorrhagic 
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stroke, Ischemic heart disease, congestive cardiac failure, renal 
insufficiency, obstructive sleep apnoea, till cardio vascular death that 
continue down to at least 115/75 mmHg
1 
. 
Hypertension is one of the component of the metabolic syndrome and 
increased levels of triglycerides, cholesterol, LDL, VLDL, with decreased 
levels of HDL has been associated with hypertension
13
. Metabolic syndrome 
comprises a group of parameters that predicts the risk of occurrence of 
cardiovascular disease and diabetes mellitus.  
Hypertension and dyslipidaemia are part and parcel of metabolic 
syndrome that has clearly shown to increase the risk for cardiovascular 
morbidity, mortality and for occurrence of diabetes mellitus. 
      Uric acid is one of the by-products of metabolism of purine produced in 
blood from endogenous purine (2/3) substances or from diet (1/3). Uric acid 
is considered to be one of the independent risk factor for hypertension and its 
levels also tend to correlate with severity of hypertension
6-12 
. Uric acid is 
tend to have a pathogenic part in hypertension mediated by various actions 
such as inflammation, vascular smooth muscle  cell proliferation in renal 
microcirculation, dysfunction of endothelium and the renin  angiotensin– 
aldosterone system activation
4 
. 
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Dyslipidemia has been found associated with elevation of uric acid 
levels and raise in any one of the lipid parameters has been found to increase 
the uric acid level.  
Uric acid is not considered a criterion for the diagnosis of metabolic 
syndrome, but some studies have observed a correlation between high levels 
of uric acid and the metabolic syndrome in different populations
18
. 
     Hence we here by analyse the uric acid levels in essential hypertensive 
individuals, lipid parameters in essential hypertensive and we seek to 
establish a correlation between uric acid levels and dyslipidemia in essential 
hypertensive individuals. 
 
 
 
 
 
 
 
 
4 
 
 
AIMS & OBJECTIVES 
1. To measure the fasting serum uric acid levels in essential hypertensive 
individuals aged between 35 to 65 years and in healthy individuals 
aged between 35 to 65 years. 
2. To measure the fasting serum levels of lipid parameters triglycerides, 
total cholesterol, LDL, VLDL and HDL in essential hypertensive 
individuals and healthy individuals aged between 35 to 65 years 
3. To analyse the possibility of correlation existing between fasting 
serum uric acid levels and fasting serum lipid parameters. 
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REVIEW OF LITERATURE 
HYPERTENSION 
Hypertension is one of the leading causes of morbidity and mortality 
adding to the global burden of non-communicable diseases
28, 29
. It not only 
causes millions of deaths, but also billions of disability adjusted life years all 
over the world
22
. Hypertension increases the risk of cardiovascular pathology 
like coronary artery heart disease, heart failure, renal diseases and peripheral 
vascular pathology.  
Its incidence is phenomenally increasing over the years, especially in 
developing countries rather than developed countries
1
. The awareness of this 
disease is quite low among people, especially among the lower 
socioeconomic status adding to increased mortality and morbidity. The 
measures to control the disease were in great vein, owing to the lack of 
awareness and ineffective treatment
4
. 
           The prevalence of hypertension has been found to increase with age, 
owing to the vascular changes that occurs over the period of time
44
. An 
increase incidence of hypertension is especially seen over the age of 50 years 
due to the atherosclerosis of blood vessels contributing to hypertension
27
. 
Recent Framingham Heart Study reported that there is an increase in 
the hypertension in the age above 50 years and it may be due to factors such 
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as decreased elasticity of the arterial wall and weight gain with age
28
. 
Hypertension is an independent risk factor for cardiovascular morbidity and 
mortality.  
         This relation it shares with cardiovascular risk is continuous and also 
consistent. Studies have shown that this risk attributed to occurrence of both 
stroke and cardiovascular morbidity have a linear relationship  from levels of 
blood pressure 115mm systolic and 75 mm diastolic  and level of risk 
increases progressively from there.  
This purported risk appears to be seen in all age groups starting from 
the age of 40 years. Systolic blood pressure when treated and decreased by 
5-6 mmhg in hypertensive confers decreased relative risk of 35 to 40% for 
stroke and 12 to 16% for cardiovascular heart disease.  
DEFINITION: 
Hypertension can be defined as a level of blood pressure of 140/90 
mm Hg or higher than that, and the value above which the treatment benefits 
seems to overcome the risks.  
Prehypertension can be defined as blood pressure elevation between 
120/80 and 139/89 mm Hg, so that the risk of progressing to hypertension is 
more when compared with the persons with blood pressure of 120/80mmhg 
and there is an increased risk of cardiovascular risk with that level of blood 
7 
 
pressure. The cardiovascular mortality rate seems to be increased, but it is 
unclear that the persons can benefit from treatment. 
EPIDEMIOLOGY: 
The prevalence of hypertension in the past in India varied differently 
between different populations. In rural populations it is higher with a 
incidence of 2 to 15 % and in relative comparison it is lesser in urban cities 
with a incidence of about 2 to 8%
30
.  
The incidence is quite going up recently in both of these areas and 
now it is estimated that the incidence is about 25% in urban population and 
10-15% among rural population
31
. With analysis from various studies, it has 
been found that occurrence of coronary artery disease and stroke have 
increased tremendously in the population of India. 
  According to the study of Inter stroke and Inter heart, the occurrence 
of hypertension constitutes about 18% and 35% of population at risk 
respectively for various cardiovascular risk factors for coronary disease and 
stroke. There are severe regional variations noted in cardiovascular related 
death in India among both sexes.  
The death rate has been found to be high in southern parts, north 
eastern areas in both sexes, while death rate found to be low in the central 
Indian parts of Bihar, Rajasthan and Uttar Pradesh
32,33
. 
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The prospective phase of the on-going Million Deaths Study from 
2004-2013   emphasises on regional variations and patterns of death 
happening in India. 
All these statistics implies that there is steady rise in the number of 
hypertensive individuals in India, when compared with the past and it goes a 
steady uphill course, especially in rural areas when compared with urban 
population due to major unawareness. 
STAGING: 
     Hypertension is staged according to the guidelines given by the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure  - seventh report – (JNC 7)34 . 
 
TABLE 1: JNC 7 - STAGING OF BLOOD PRESSURE 
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In contrary to the staging given earlier by JNC VI report, a newer 
stage designated as Prehypertension is added . Stage 3 of hypertension which 
is presented in JNC VI is taken off, instead it is combined and newer staging 
of stage 2 with predefined value is provided. 
CLINICAL DISORDERS OF HYPERTENSION: 
ESSENTIAL HYPERTENSION:         
       Patients with hypertension without any specific underlying disorder 
responsible for elevation of blood pressure are categorised as ESSENTIAL 
HYPERTENSION. It can also be defined as Primary hypertension or 
Idiopathic hypertension. 
SECONDARY HYPERTENSION: 
Patients who have specific aetiology for the elevation of blood 
pressure are categorised as SECONDARY HYPERTENSION. They amount 
to about 5 to 20% of hypertensive population. The specific mechanism 
causing blood pressure elevation is more often apparent in this group of 
patients
36
. 
CAUSES OF SECONDARY HYPERTENSION: 
 Renal Hypertension - Parenchymal 2-3% 
 Renovascular 1 – 2% 
10 
 
 Endocrine Hypertension - Primary hyperaldosteronism 0.3% 
 Cushing syndrome < 0.1% 
 Pheochromocytoma < 0.1% 
 OCP induced 2 – 3% 
 Miscellaneous 1% 
  Coarctation of aorta,  
 polyarteritis,  
 neurogenic, 
  drug induced like 
 sympathomimmetics -ephedrine, phenylephrine 
 monoamine oxidase inhibitor, ergot alkaloids 
 Non-steroidal anti-inflammatory drugs 
 Glucocorticoids, oestrogen 
  caffeine 
 ethanol 
  Nicotine. 
ISOLATED SYSTOLIC HYPERTENSION: 
 SBP ≥140 mmHg and DBP <90 mmHg. 
SBP is staged appropriately as above. 0.8% in 50 years, 5% in 60 
years, 12.6% in 70years, 23.6% in 80 years has isolated systolic HTN
37
. 
Higher in women and black subjects compared with men and white subjects. 
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PATHOPHYSIOLOGY:  
Decrease is arterial compliance is proposed. Level of SBP is related to 
maximal blood flow velocity in large arteries, which in early phase of 
cardiac cycle, depend on heart and pulse wave velocity and in later phase 
depend on number of reflected waves. Pulse wave velocity is inversely 
related to distensibility of large artery, which is responsible for faster 
outflow of blood in diastole and result in decrease diastolic blood pressure. 
 
TABLE 2: SYSTOLIC HYPERTENSION WITH WIDE PULSE 
PRESSURE 
HIGH RENIN ESSENTIAL HYPERTENSION:  
Some patients with labile hypertension and mild essential 
hypertension have tachycardia with increased cardiac output but normal 
peripheral resistance. This is indicative of hyperkinetic circulation, due to 
beta-adrenergic activity. 
12 
 
Such patients have elevated plasma renin activity known as High renin 
Essential hypertension. 
LOW RENIN ESSENTIAL HYPERTENSION: 
Some patient might have low plasma rennin with high BP. But 
majority of them have normal plasma renin activity. 
 
TABLE 3:  SECONDARY CAUSES OF SYSTOLIC AND DIASTOLIC 
HYPERTENSION 
WHITE COAT HYPERTENSION:  
The phenomenon in which BP is elevated,in presence of health 
professional, while measuring BP
45
. First, described by RivaRocci more than 
100 years ago. Since 24 hour ambulatory blood pressure monitoring was 
introduced
25
, White coat hypertension was redefined as abnormal clinic BP, 
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but normal ABM. According to JNC- 7th, upper limit of normal ABM 
should be 135/85mmHg, while patient is awake and 120/75mmHg while 
asleep
26, 27
. WHO/ISH guidelines suggest that 24hr average of Home BP of 
120/80mmHg correspond to clinic BP of 140/90mmHg. 
Prevalence of WCH is 21% of all hypertensive and more likely to be 
females. Studies suggest WCH is associated with End Organ Damage. It 
should to perhaps be treated as “Pre Hypertensive State”. 
GENETIC CONSIDERATIONS: 
Hypertension is disorder which is representative of polygenic type, in 
where various gene combinations along with environmental exposures to 
cause elevation of blood pressure.  Various subsets of genes may lead to 
various physical characteristics linked with hypertension such as 
dyslipidemia and obesity
38
. 
On-going analysis tells that genes that represent parts of  system of the  
renin-angiotensin-aldosterone , along with angiotensinogen and angiotensin-
converting enzyme (ACE) polymorphisms, seems to be associated with 
causation of hypertension
39
 . 
Various other genes that are proposed to have association with 
hypertension are recently found out.  Genome wide association studies 
14 
 
utilise   scanning markers across the entire part of the genome to identify loci 
which are in relation with blood pressure
40
.  
 Due to the presence of rare monogenic hypertensive diseases, the 
genetic variants associated with hypertension needs to be confirmed, and the 
various steps by which these variants affect blood pressure remain to be 
determined. 
MECHANISMS OF HYPERTENSION: 
The factors that are associated with the control of normal and 
increased arterial pressure have to be analysed to understand the underlying 
pathogenesis of hypertension. The two factors that decide the blood pressure 
are peripheral resistance and the cardiac output.  Cardiac output is in fact 
contributed by the heart rate and stroke volume. The contractility of heart 
and vessel wall architecture and its size contributes to the stroke volume. 
The anatomy of small arteries and arterioles and its changes regulate the 
peripheral resistance. 
The volume that the vessel holds decides about the pressure of the 
artery. The predominant ion that determines the volume of the vessel is 
sodium ion. when the intake of the sodium ion increased more than to be 
excreted by the kidney ,the volume inside the vessel increases initially and 
the output of the heart also increases. But if persistent amount of blood flow 
15 
 
has to be preserved to a particular organ, the resistance has to be increased at 
that site, to maintain auto regulation. 
The increase in the blood pressure at first is contributed mainly by 
increase in the output of the heart, but as the time goes on there is an 
increase in peripheral resistance and the output of the heart changes to 
normal. The impact of sodium on the rise in blood pressure is affected by its 
relation it shares with chloride. The salts of sodium with no chloride content 
have little impact over the elevation of blood pressure
47, 48
. 
At first, the excretion of sodium in the urine increases due to the 
increase in the arterial pressure effected by the high sodium chloride intake. 
An increase in the rate of glomerular filtration, atrial natriuretic factor and 
the decline in the absorbing capacity of the renal tubules, all contribute to the 
pressure natriuresis  effect. When the ability to excrete sodium is affected, 
the arterial pressure will increase and achieve natriuresis
17
. 
The ability of kidney to excrete sodium is affected by the intrinsic 
disease of the kidney, an elevated production of mineralocorticoid hormone 
and this contributes to sodium chloride dependent hypertension. 
The absorption of sodium by the kidney is increased by the neural 
activity to the kidney. An increased amount of arterial pressure is required to 
16 
 
reach the required sodium balance. When the sodium is lost in certain 
conditions, the blood pressure will be low in that state
19
. 
AUTONOMIC NERVOUS SYSTEM: 
The pressure, volume and chemoreceptor signals are the ones by 
which the autonomic nervous system maintains the cardiovascular stability. 
The regulation of blood pressure is done by the adrenergic reflexes in the 
recent periods, and the hormonal and other volume associated factors 
determine the blood pressure in long run. Norepinephrine, epinephrine, and 
dopamine are the three catecholamine, which are produced endogenously. 
The tonic and phasic cardiovascular activity is maintained by all these three 
endogenous catacholamines. 
The G proteins are the ones which mediate the activities of the 
adrenergic receptors and the activity is also regulated by downstream second 
messengers. The agonists for adrenergic receptors subtypes with varying 
affinity are the epinephrine and norepinephrine.  The adrenergic receptors 
are divided into alpha and beta depending upon their physiology and 
pharmacology.  They are further subdivided into alpha1, alpha2,beta1 and 
beta2. 
The number of adrenorecptors is affected by the circulating 
catecholamine levels. High levels of catecholamine can down regulate the 
17 
 
receptors in different tissues. The blood pressure is regulated constantly by 
several reflexes. The arterial baroreflex is regulated by stretch sensitive 
receptors in carotid sinus and aortic arch. These baroreceptors fire in an 
increasing order when arterial pressure increases and this decreases the 
sympathetic outflow which causes decrease in heart rate and arterial 
pressure. Any sudden fluctuation in arterial pressure is regulated by this 
mechanism. But if the patients are affected by autonomic neuropathy, these 
baroreceptor reflex mechanisms are blunted and they are prone to more 
labile blood pressure
49
. 
    The sympathetic outflow is increased in both the normal and obese 
individuals with hypertension. In obstructive sleep apnea also, an increase in 
sympathetic outflow is observed.  Sympathetic nervous system is the one 
which plays a vital role in the maintenance of arterial pressure. 
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM: 
The regulation of arterial pressure is effected by vasoconstriction, 
which in turn is mediated by angiotensin II and the aldosterone which causes 
retention of sodium. The stimulus for renin secretion comes from three 
mechanisms. 
1. The transport of sodium chloride when decreased into thick ascending 
limb of loop of henle. 
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2. The  stretch in the renal afferent arteriole when decreased  
3. The stimulation of sympathetic nervous system by adrenergic 
receptors. The secretion of renin is inhibited by the increased sodium 
chloride entry in the ascending limb of loop of henle. The secretion of 
renin is inhibited by angiotensin II directly and there is an increased 
secretion of renin when receptors of ACE is blocked
49
. 
    Angiotensin II is a powerful pressor substance, and it stimulates the 
secretion of aldosterone by the adrenal zona glomerulosa.  It is a powerful 
mitogen that growth of myocyte and vascular smooth muscle cell 
stimulation. Angiotension II receptors are also found in various parts of the 
kidney and they cause sodium excretion, dilation of vessels, formation of 
matrix and inhibition of cell growth. And they contribute to the maintenance 
of glomerular filtration rate. A block in AT I will cause an increase in AT II 
activity
49
. 
Renin mediated hypertension is observed in renovascular 
hypertension. The renal artery when obstructed leads on to decrease in renal 
perfusion pressure and thus stimulates the renin secretion. But as the time 
goes on, as a result of secondary renal damage, there is a less renin 
dependency noted in this kind of hypertension. 
Even though, aldosterone secretion is increased by ACTH , it is not 
vital factor for chronic modulation of aldosterone 
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Sodium reabsorption can be affected by aldosterone by means of amiloride-
sensitive epithelial sodium channels in the renal collecting duct. Sodium is 
exchanged for potassium and hydrogen ions and hence electric neutrality is 
regulated by aldosterone. So hypokalemia and alkalosis can occur by 
increase in secretion of aldosterone. 
Non epithelial cell are also affected by aldosterone. It causes changes 
in structure and function in vital organs including kidney, heart, blood 
vessels resulting in varied consequences such as fibrosis of myocardium, 
nephrosclerosis, inflammation of vessel wall and remodelling due to 
oxidative stress 
 
FIGURE 1: Renin angiotensin aldosterone axis 
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The elevated action of the renin-angiotensin-aldosterone axis has been 
associated with hypertension invariably. Whenever there is a decreased 
sodium chloride diet is taken, or when a volume contraction occurs, there is 
an increased action of renin angiotensin aldosterone axis and there by 
maintaining the arterial pressure. A secondary elevation of aldosterone also 
occurs in edematous states such as congestive cardiac failure and liver 
disease
103
. 
VASCULAR MECHANISMS: 
The radius of vessel and the compliance of arteries play a vital role in 
the determination of arterial pressure. The blood flow is inversely 
proportional to the size of the lumen and hence the small changes in the size 
of the vessel will influence the resistance. The changes in functional, 
structural and mechanical levels in hypertensive patients will cause the 
lumen diameter to be reduced and hence causing the elevation of blood 
pressure. When alterations in vessel wall happen without variation in vessel 
volume, it will result in remodelling.  
There is an increase in peripheral resistance noted due to hypertrophic 
or eutrophic remodelling. Low-grade inflammation, vascular fibrosis and 
apoptosis will also influence remodelling. The elasticity of the vessel will 
also influence the lumen diameter. 
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The arterial stiffening and arteriosclerosis in the hypertension causes 
high systolic blood pressure and decreased vascular compliance due to 
structural changes can cause a wide pulse pressure. The stiffness of arteries 
can independently predict the risk of cardiovascular events. 
The transport of ions in vascular smooth muscle cells influence the 
vascular tone and growth, and hence causing the elevation in blood pressure. 
These vascular tone and vascular growth is modulated by in trace. 
The vascular tone is modulated by endothelial function and nitric 
oxide modulates the vascular tone by causing vasodilation. There is an 
impairment of endothelium dependent vasodilation that occurs in 
hypertensive. A vasoconstrictor called Endothelin is synthesised by the 
endothelium, and the antagonists of endothelin may decrease the blood 
pressure in individuals with resistant hypertension. 
MEASUREMENT: 
Sphygmomanometer is the instrument used to measure BP. Both 
mercury and aneroid types are used. But sometimes reading were found 
inaccurate, unreliable due to extreme bouncing, illegibility of gauge, 
blockage of the filter, lack of mercury in reservoir, bladder damage, rubber 
aging and leaks
50
. So these things have to be corrected before recording BP.  
22 
 
The movement of the arms can cause notable artefacts in measurement 
of blood pressure, systolic pressure becomes higher. Guidelines given by the 
world health organisation recommended that cubital fossa should be kept at 
the level of 4
th
 ICS
51
.  
The American Heart Association states the heart level as “Arbitrarily 
taken to the junction of 4
th
 ICS and lower left sternal border. Practical 
clinical guide defines it as “When the patient is seated placing the arm on a 
nearby table top, a little above waist level is the satisfactory position
52
. 
Home measurements by patients itself is similar to ambulatory BP 
monitoring. ABM is acceptable to patients. But self-measurement is not 
possible
50
. Several studies show that measurement of blood pressure in home   
and by giving  numerous recordings of blood pressure  under relatively 
stable condition  is beneficial and there by evading White Coat hypertension, 
and so considered  superior to hospital  measurement, in terms of association  
with organ damage, rehabitility and  assessing the predictive value of 
cardiovascular pathology .American Heart Association found that not one of 
114 participating cardiologist followed all techniques of office BP recording.  
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DETERMINANTS OF HYPERTENSION: 
1. WEIGHT GAIN 
It is major controllable risk factor for new onset of HTN. Abdominal 
obesity as evidenced by waist circumference of ≥ 85 cm in women &≥98cm 
in men. 1mmHg of SBP rise for every 2 Lb weight gain. 
2. SALT INTAKE 
Salt sensitivity is in raise with BP. BP increase with salt intake and BP 
decreases with salt restriction
47
. It is common in black. Salt that is consumed 
in the diet regulates the production of transforming growth factor beta in the 
kidneys that is linked to hypertension related cardio-renal complication. TGF 
–ß was observed to be increased in black individuals with incidence of 
hypertension.  
3. ALCOHOL INTAKE
 
Consumption of low to moderate amount of alcohol also associated 
with a high risk of hypertension in blacks. Alcohols accounts for 5-30% of 
all HTN. 
4. PHYSICAL ACTIVITY 
Sedentary individuals have 20 – 50% increase risk of developing 
hypertension. Regular exercise lowers BP.  
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5. SMOKING 
      Smoking reported to cause acute rise of BP. However relationship 
between smoking and level of BP is not reported.  
6. SOCIOECONOMIC STATUS 
Hypertension has more prevalent in upper socio economic group and 
developed   countries. 
Improving lifestyles is key in treatment, not just pharmacologic 
therapy, National recommendation and legislation of Finland, include 
labelling salt content of commercial prepared food and use potassium, 
magnesium enriched minerals salt instead of common salt in home and food 
industry.  
7. EFFECT OF EXERCISE 
There is an inverse relationship between physical activity and BP. The 
effect of exercise is more pronounced in hypertensive than in normotensives. 
However exercise is less effective than diet in lowering BP. The 
vascular resistance of systemic circulation is decreased due to exercise. 
Because of the vasodilatation in working muscles, there is an increase 
in the output of the heart and a marginal rise in diastolic and notable rise in 
systolic blood pressure is noticed. Once when exercise is over, the output of 
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the heart decreases fastly and this will lead on to decrease in the blood 
pressure than prior to exercise. 
Along with these vasodilatory mechanisms, a decrease in the activity 
of the sympathetic nervous system is also observed. 
So in order to prevent and effectively treat hypertension, modification 
of life style and behavioural changes are needed in the form of aerobic 
exercises done regularly and consistently, a decreased dietary sodium intake 
weight loss and moderate intake of alcohol.  
SYMPTOMS AND SIGNS: 
HISTORY: 
The hypertensive patient must be evaluated with a good history and 
thorough examination to validate the diagnosis of hypertension initially and 
then a systematic and methodical examination is done to find the secondary 
causes that contribute to hypertension, assessing the risk factor for 
cardiovascular disease, to find the complications and the end organ damages 
caused by the hypertension. 
    History pertaining to any particular life style, that poses a threat to the 
causation of hypertension, so that a life style modification and behavioural 
therapy can be given. 
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Most of the individuals in which the hypertension was diagnosed 
show no particular symptoms pertaining to their increase in the blood 
pressure. When the blood pressure elevation is severe in the patients,  they 
usually complaint of headache. The headache occurs especially early in the 
morning and it occurs in the back of the head at the occipital region. 
    Many other symptoms can occur in hypertension and they are 
considered nonspecific. Easy fatigability, palpitations, dizziness, impotence 
can be present in individuals with elevated blood pressure and they are 
considered nonspecific. 
When the patients have specific symptoms, it usually denotes there is a 
underlying cause for the elevation of blood pressure and so it can be 
observed that patient can have secondary hypertension
49
. 
 
TABLE 4: Relevant history in hypertension 
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PHYSICAL EXAMINATION: 
In a hypertensive individual, height of the patient measured, weight of 
the patient weighed and then body mass index calculated to observe any 
obesity. The blood pressure is measured in both the upper limbs and it is also 
taken with patient in supine, lying and standing position, to observe for the 
occurrence of postural hypertension. 
The blood pressure should also be taken in the lower limb once, if the 
individual is young and his age is below 30 years. The heart rate should also 
be counted in the patient.  
The pulse should be palpated for any irregularity, since in 
hypertensive patients, an increased incidence of atrial fibrillation is found 
out. The patient neck is examined and observed for any enlargement of the 
thyroid gland and patient looked for any signs pertaining to hypothyroidism 
and hyperthyroidism.  
Patient should be examined for any bruits present for carotid and 
femoral arteries, his fundus should be examined with fundoscope and 
femoral, dorsalis pedis pulse should be palpated. When doing a fundsocopic 
examination any increase in the arteriolar light reflex, arteriovenous crossing 
anomalies, retinal hemorrhages, cotton wool spots and hard exudates has to 
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be seen, since they can imply about the severity of hypertension. 
Papilloedema can be observed in patient with malignant hypertension. 
     In the cardiovascular examination, one can observe a loud second 
heart sound, S4 gallop due to the noncompliance of the left ventricle. The 
apical impulse when palpated will be displaced down and out, and it will be 
well sustained in nature.  
When you can auscultate an abdominal bruit, a possibility of 
renovascular hypertension can be considered. When kidneys are palpable in 
examination of abdomen, then possibility of polycystic kidney should be 
considered. 
    Any other signs of heart failure should be found out and thorough 
neurological examination should also be carried out to exclude neurological 
causes. 
INVESTIGATIONS: 
 24 hrs urinary sodium excretion and sodium/potassium ratio are 
strongly associated with BP. Serum ionized calcium concentration was 
decreasing significantly in elderly subjects and it worsened their prognosis. 
High LDL concentration in seen in elderly hypertensive. Negative 
correlation between ionized calcium and triglyceride were found in young 
and elderly hypertensive. In young, non-dippers (BP doesn‟t fall nocturnally) 
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suggest poor cardiovascular prognosis. 
 
TABLE 5: Laboratory investigations in hypertension 
AGING AND HYPERTENSION: 
     Structure and function in the microcirculation get altered and they are 
vital factors contributing to pathology in vascular disease such as 
hypertension. Capillary pressure is rises in primary hypertension, and this is 
due to decrease in number of capillaries or pathology in vascular responses 
at a precapillary or postcapillary level. 
    Both capillary rarefaction and altered responses in microvasculature 
have been seen before the onset of clinical hypertension, implicating their 
part in etiology.   
Aging has been associated with dysfunction of endothelium, because 
of a decrease in NO and prostanoid pathways. 
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 In aging, however hypertension is largely contributed due to altered large 
artery stiffness. 
MONOGENIC HYPERTENSION: 
Various forms of monogenic hypertension have been found out. They 
are found by their characteristic phenotypes, and the diagnosis may be 
confirmed by genetic analysis. Different   inherited disorders in adrenal 
steroid biosynthesis lead to mineralocorticoid-induced hypertension and 
hypokalemia. In 17-hydroxylase deficiency, sex hormones and cortisol is not 
synthesised adequately. Their sexual maturation is at stake. Males could 
present as pseudo hermaphrodite and females could present as primary 
amenorrhea and absent secondary sexual characteristics. 
Increased synthesis of mineralocorticoids will lead on to hypertension, 
especially when enzymatic block occurs proximally, leading on to 
accumulation of  desoxycorticosterone. An 11-hydroxylase deficiency leads 
to increased synthesis of mineralocorticoids and diversion of steroid 
synthesis into the androgen pathway.  An 11-hydroxysteroid dehydrogenase 
deficiency has an impaired ability to metabolize cortisol to its inactive 
metabolite and this leads on to hypertension.  
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This defect could be acquired, and in some cases inherited and may be 
due to licorice-containing glycyrrhizin acid. The same substance is present in 
the chewing tobacco paste of several brands.  
The Liddle's syndrome occurs due to constitutive activation of 
amiloride-sensitive epithelial sodium channels present on the distal renal 
tubule, resulting in excess sodium reabsorption; in pregnancy exacerbation 
of hypertension occurs because of activation of the mineralocorticoid 
receptor by progesterone. 
COMPLICATIONS OF HYPERTENSION: 
 Hypertension if found out has to be treated promptly, otherwise lack 
of treatment can result in dire consequences. Hypertension can result in 
mortality due to coronary artery heart disease, heart failure, stroke and renal 
failure if not treated properly. 
 When the elevation of blood pressure is rapid, and if it is in an 
accelerated fashion then patient can due to renal failure frequently. 
OPHTHALMIC CHANGES IN HYPERTENSION: 
The only tissue in the body in which arteries, arterioles, veins that can 
be visualised directly is the retina of the eye. 
Changes in the arteries and veins can show the severity of 
hypertension and thereby we can grade the retinopathic changes according to 
the severity. 
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Fundoscopic examination is thus helpful in treating the potential 
retinopathic changes as well as the severe hypertension when present can be 
brought to the notice by this examination. 
The retinal changes in hypertension is graded by various systems and 
one among them is the The Keith Wagener  Barker classification and it 
grades the severity of hypertension according to the fundoscopic changes 
seen. 
 
TABLE 6: The Keith Wagener Barker Classification of Hypertensive 
Retinopathy 
HYPERTENSION AND HEART: 
The stiffness and hypertrophy occurs in the heart because of the undue 
tension on the myocardium of the left ventricle and this increases the 
development of atherosclerosis in the vessel walls of the heart. Left 
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ventricular systolic function is compromised in long run and initially patient 
has diastolic function of the heart compromised with lower E/A ratio and 
increased isovolumetric relaxation time.  
These changes can be visualised and observed in the echocardiogram. 
LEFT VENTRICULAR HYPERTROPHY: 
Hypertrophy of the left ventricle of the heart occurs due to the 
elevated afterload with which heart has to contract against. This is in due 
course can result in left ventricular systolic dysfunction. 
An abnormal diastolic filling pattern of the left ventricle and left 
ventricular wall mechanics appears to be compromised when seen in 
echocardiogram. The vasodilatory capacity of the coronary arteries gets 
reduced often. 
 
FIGURE 2: Left ventricular hypertrophy 
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HEART FAILURE: 
The left ventricular systolic dysfunction and the diastolic dysfunction 
will affect the capacity of heart to pump the adequate blood out and this can 
result in heart failure. An increment in the systolic blood pressure increased 
the risk of patient developing heart failure according to the Framingham 
heart study
96
. 
When the left ventricular systolic dysfunction is severe, the ejection 
fraction starts falling and due to the decreased compliance of the left 
ventricle patient ultimately goes to the pulmonary edema if the hypertension 
not treated promptly. 
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FIGURE3: Complications of hypertension 
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FIGURE4: Concentric hypertrophy of the heart seen in hypertensive 
patient 
CORONARY HEART DISEASE: 
Hypertension is one of the important factors posing a risk for the 
patient to develop coronary artery heart disease and myocardial infarction. 
Uncontrolled hypertension will result in the coronary angina pain and will 
result in cardiovascular morbidity and mortality. 
The prognosis of the coronary heart disease and myocardial infarction 
also depends upon the blood pressure which is present before and it is also 
influenced by the control in the near future. The myocardial infarction can 
occur silently and this proportion seems to be increased in the hypertensive 
population rather than in normal population.  
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The silent myocardial infarction can result in sudden cardiac death and 
they are at increased risk for the cardiovascular morbidity and mortality. 
HYPERTENSION AND KIDNEYS: 
An unnoticed small dysfunction of kidneys will result in the 
development of primary hypertension. Recently kidneys are the targets of 
research in searching for the etiology of primary hypertension especially the 
pressure natriuresis effect in the kidneys. Any renal mishandling of salt and 
water will result in the retention of salt and consequently solvent retention 
resulting in the development of hypertension. 
The hypertensive individuals show microalbuminuria which indicates 
the underlying structural and functional dysfunction causing the 
intraglomerular hypertension.  
Whenever microalbuminuria is seen in hypertensive individuals, they 
should be evaluated for left ventricular hypertrophy and carotid artery 
thickness, since they show a strong correlation with each other. 
When nephroscleosis happens as a result of ongoing hypertension, the 
plasma creatinine level will be elevated indicating the renal failure and 
patient goes in for complete renal insufficiency. 
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HYPERTENSION AND CENTRAL NERVOUS SYSTEM: 
Cerebrovascular accidents are found with an increasing incidence in 
patients with hypertension. Ischemic stroke as well as hemorrhagic stroke 
tends to be increased in hypertensive individuals and hypertension is one of 
the independent risk factor for the occurrence of stroke. 
     Lacunar infarcts are more common in patients with hypertension. 
White matter lesions in cerebral cortex have been picked up in MRI BRAIN 
about 45%.  
    Most of the strokes due to hypertension are due to infarction and 
others are because of intracerberal haemorrhage or subarachnoid 
haemorrhage. When the hypertensive individual is above 65 years, the risk 
of the patient developing stroke is very high due to the proportional increase 
in blood pressure with age. 
     Impairment of cognition has been found in the hypertensive patients 
and this is attributed to multiple lacunar infarcts due to small vessel disease 
culminating in white matter dementia. 
    In patients with hypertension, when blood pressure elevated beyond a 
certain level, auto regulation of cerebral blood flow is lost and patient lapses 
into encephalopathy.  
   When hypertension not promptly treated, patient will progress in to 
stupor, coma and even death within hours. Care must be taken to 
differentiate hypertensive encephalopathy from other neurological disorders, 
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so that appropriate treatment will save the life of the patient. 
HYPERTENSION AND PREGNANCY: 
Hypertension in pregnancy usually appears after 20 weeks of gestation 
and about 15% of these conditions develop in previously normotensive 
women. Nearly 50% of these women will go on for preeclampsia which is 
complicated with pedal edema, proteinuria with risk of going into eclampsia 
which is complicated by seizures. 
    In individuals with history of hypertension before pregnancy, they are 
at more risk for developing preeclampsia and eclampsia when compared 
with normotensive women developing hypertension. 
Women who are progressing for preeclampsia are at higher risk of 
delivery small for gestatiaonal babies due to a placental compromise. 
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DYSLIPEDEMIA 
LIPIDS: 
Definition: Lipids are compounds relatively insoluble in water, but freely 
soluble in non-polar organic solvents like Benzene, Ether etc., 
CLASSIFICATION: 
1. SIMPLE LIPIDS: They are esters of fatty acid with glycerol or higher 
alcohol
66
. 
A. Triacylglycerol 
B. Wax 
2. COMPOUND LIPIDS: They are fatty acid esterified with alcohol, but in 
addition contain other groups 
a) . Phospholipids like 
 Lecithin 
 Cephalin 
 Phosphatidyl Serine 
 Phosphatidyl Inositol 
 Phosphatidyl Glycerol 
 Plasmalogens 
 Sphingomyleins 
b). Non Phosphorylated Lipids 
 Glycolilpids - Cerebrosides 
 Globosides 
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 Gangliosides 
 Sulpho Lipides 
3. DERIVED LIPIDS: Compounds derived from lipids or precursors of 
lipids 
Eg. Fatty Acid, Steroids, Prostaglandins, Leukotrienes, Terpenes, Dolichols 
etc., 
4. LIPID COMPLEX : Proteolipids and Lipoproteins
101
. 
 FUNCTION OF LIPIDS: 
1. Storage from of energy – Triacyl glycerides 
2. Structural components of Bio membranes – Phospholipids Cholesterol 
3. Providing Insulation against changes in external temperature – 
Subcutaneous fat. 
4. Giving shape & contour to the body 
5. Protecting internal organs by providing a cushioning (Pads of fat) 
6. Metabolic regulators (steroid, Hormones, Prostaglandin) 
7. Acting as surfactants, detergents, emulsifying agents 
8. Acting as Electric insulators in neurons. 
9. Help in absorption of Fat soluble vitamins (A, D, E, and K) 
10. Add taste & palatability to food. 
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LIPID METABOLISM: 
Triacylglycerides or Triglycerides are esters of glycerol, containing 3 
fatty acids attached to 3 Carbon alcohol of glycerol. Both animals & plants 
are the source of triglycerides. Triglycerides from plants have long chained 
unsaturatedfatty acids. So it is liquid at room temperature. But animal 
triglycerides have medium chain saturated fatty acids. So, solids at room 
temperature
112
. 
METABOLISM OF TRIGLYCERIDES: 
Triglycerides are digested in duodenum and proximal ileum. 
Pancreatic and intestinal lipase hydrolyse to glycerol, monoacyl glycerol and 
fatty acids. After absorption, Triglycerides are resynthesied in intestinal 
epithelial cells and combine with cholesterol and Apo B-48 to form 
Chylomicrons. Chylomicrons are secreted to lymphatic system travel 
through thoracic duct and reach blood stream through Jugular vein. 
LIPOPROTEIN  
DEFINITION:  
Lipids synthesis in liver & intestine are insoluble. So they are 
transported to various tissues for metabolic functions through formation of 
macromolecular complex called Lipoproteins. They are spherical particles 
with nonpolar lipid core containing Triglycerides and cholesterol esters. 
Peripheral polar lipid contains phospholipids and free cholesterol near 
surface
101
.  
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They also contain specific proteins called Apolipoproteins located on 
surface. They are non-covalently attached through hydrogen bond and 
vander  waals force.  
Binding of lipids to protein is loose enough to allow ready exchange 
of lipids among the plasma lipoprotein and between cell membranes and 
lipoprotein
64
. 
TYPE OF LIPOPROTEINS: 
Based on hydrated densities, separated by ultra-centrifugation: 
  Chylomicrons 
  Very low Density Lipoprotein 
 Intermediate Density Lipoprotein 
  High Density Liproprotein 
  Lipoprotein a. 
APOLIPOPROTEINS:  
It is protein component of lipoproteins. They are present in various 
proportions in all lipoprotein. 
 Apo A-I, Apo A-II, Apo A IV 
 Apo B-100, Apo B-48 
 ApoC-1,ApoC-II,ApoC-III 
 Apo-E, 
 Apo (a) 
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FUNCTION OF APOLIPOPORTEIN: 
1. Activating important enzymes in lipoprotein metabolic pathway. 
2. Maintain structural integrity of lipoprotein complex 
3. Facilitating uptake of lipoprotein into cells through their recognition by 
specific cell surface receptors
62
. 
 
TABLE 7: Composition of lipoprotein 
LIPOPROTEIN METABOLISM  
PATHWAYS OF LIPOPROTEIN METABOLISM 
1) Endogenous pathway 
2) Exogenous pathway 
3) Intracellular LDL receptor 
4) HDL Reverse – Cholesterol pathway 
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1. EXOGENOUS PATHWAY (CHYLOMICRON): 
Lipoprotein is of dietary origin. Dietary triglycerides & Cholesterol 
esters are assembled in secretary vesicles in Golgi apparatus to form 
Nascent-chylomicrons. It is introduced into circulation through intestinal 
villi. It‟s lipid content is 90% of Triglyceride and 2% of Apo B-48 and Apo 
A. This Nascent-chylomicron acquires Apo C and Apo E from HDL to form 
Chylomicron. 
Apo C-II present on surface of chylomicron activates lipoprotein 
lipase, attached to luminal surface of endothelial cells. Lipoprotein lipase 
hydrolysis triglycerides to free fatty acids,  which can be taken up by muscle 
for energy or adipose tissue for storage. 
ApoA and some phospholipids & free cholesterol are transferred from 
chylomicron to HDL. This newly formed chylomicron is called 
chylomicron-Remnant containing 80% TGL, % Apo B-8 & Apo E. 
Presence of Apo B-48 & Apo E is recognized by specific hepatic 
remnant receptor and internalized by endocytosis. Lysosyme hydrolyse 
chylomicron remnants & from bile acids. This is incorporated into newly 
formed lipoprotein or stored as cholesteryl ester. 
2. ENDOGENOUS PATHWAY: 
Lipoprotein is of hepatic origin. Triglycerides, Cholesterol can be 
synthesised in liver. This endogenous Triglyceride and cholesterol are 
packaged in secretary vesicles in Golgi apparatus, transported by exocytosis 
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into ECF & then into circulation, in the form of Nascent VLDL, containing 
55% TGL & Apo B-100, Apo E, small amount Apo C on its surface. 
Additional Apo E and Apo C are transferred from circulating HDL to 
nascent VLDL forming VLDL. Apo CII present on surface of VLDL 
activates LPL on endothelial cells and hydrolysis VLDL-TGL releasing free 
fatty acids and glycerol. 
During hydrolysis Apo C is transferred back to HDL. VLDL is 
converted to VLDL remnants some are taken up by liver and rest converted 
to IDL. IDL has Apo E on surface, so bind to hepatic remnant receptor 
removing 50% of IDL. Some materials from IDL, that is phospholipids, free 
cholesterol, and apolipoprotein are transferred to HDL to form HDL-
Denova. Cholesteryl esters are transferred from HDL to LDL. 
Net result of lipolysis and cholesteryl esters exchange is replacement 
of triglyceride core of VLDL with cholesteryl esters. Further IDL undergoes 
lipolysis removing of remaining triglycerides and all apolipoproteins except 
B-100 to form LDL. 
3. LDL RECEPTOR PATHWAY: 
Specific receptors present in coated pits of plasma membrane 
recognize and bind to apo B-100 of LDL. The particles are internalized in 
coated vesicle to form endosome. Receptor dissociates from LDL and return 
to cell surface. LDL migrate to lysosome, Apo- B 100 is degraded to small 
peptides and amino acids. 
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Cholesterol esters are hydrolysed and free cholesterol is available for 
synthesis of cell membranes, steroid hormones and bile acids. 
Over supply of free cholesterol leads to: 
1. Decreased rate of endogenous synthesis of cholesterol by inhibiting 
rate limiting enzyme HMG-COA reductase. 
2. Increased formation of cholestryl esters catalysed by ACAT. 
3. Inhibition of Synthesis of new LDL receptors by suppression of 
transcriptionof receptor gene. 
LDL is also taken up by extra hepatic tissues through scavenger 
receptors or nonreceptor mediated pinocytosis. The nonreceptor mediated 
uptake become significant as plasma concentration increase as in case of 
familial hypercholesterolemia. 
Nonreceptor mediated uptake is not saturated or regulated. Scavenger 
receptor is also unregulated, found in macrophages and other cells. 
Macrophages engorge cholesteryl esters and form foam cells, considered the 
earliest component of atherosclerotic lesion. 2/3rd of LDL is removed by 
LDL receptors and remaining by scavenger cell system. 
4. HDL – REVERSE CHOLESTEROL TRANSFER PATHWAY: 
HDL secreted from liver or intestine as disc-shaped nascent particle 
consist of phospholipids and ApoA-1. Triglyceride rich particles such as 
phospholipids, cholesterol and certain apolipoprotein get added to nascent 
HDL, to form spherical particles called HDL3. Cholesterol is esterified by 
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action of lecithin cholesterol acyl transfers (LCAT) in presence of cofactor 
apoA-1. So size of HDL depend on amount of accumulated 
cholesterol esters and activity of LCAT This form HDL2. 
HDL cholesteryl esters are delivered to liver by following mechanisms: 
1. Cholesteryl esters from HDL are selectivity taken by hepatic HDL 
receptors. HDL particles are returned back to circulation. 
2. Cholesteryl esters are transferred from HDL to Apo B-100 lipoprotein 
and further taken up by liver through receptors of lipoprotein. This is 
mediated by CETP (Cholesterol Ester Transfer Protein) 
3. HDL Apo E is also recognized by hepatic receptors. This process 
delivers cellular and lipoprotein cholesterol back to liver for use or 
disposal. So, called Revenue cholesterol transport system. 
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FIGURE 5: EXOGENOUS PATHWAY 
 
 
 
FIGURE6: ENDOGENOUS PATHWAY 
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FIGURE 7: LDL RECEPTOR PATH WAY 
 
 
 
 
FIGURE 8: REVERSE CHOLESTEROL TRANSPORT 
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CLINICAL SIGNIFICANCE OF LIPIDS: 
High levels of lipids easily lead to atherosclerosis, a cause of CHD. 
The association between serum cholesterol and atherosclerosis in human was 
suggested in1983. Familial aggregation of hyper cholesterolemia and CHD 
was also demonstrated.  
Risk ratio between atherosclerotic coronary disease and cholesterol is 
1 at 200 mg/dl of cholesterol value. Ratio increase to 2 at 250 mg/dl and 4 at 
300 mg/dl 53. Increased fasting hypertriglyceridemia, hypercholesterolemia, 
increased LDL and decreased HDL is associated with increased risk with 
CHD
61
. A reduction of LDL cholesterol is correlated with regression in 
atherosclerotic lesion in individual with CHD. Increased ApoB-100 and 
decreased Apo A-I is seen with CHD
62
. 
CHD is increased by saturated fatty acid and by mono and poly 
unsaturated fatty acid. BP is associated with dietary intake of saturated facts 
and inversely with dietary intake of linolenic acid. Level of palimitoleic acid 
in serum cholesterol esters, which is supposed to reflect dietary saturated 
facts, was associated with hypertension
54
. 
Lower level of plasma linoleic acid high plasma level of palmitic and 
arachidonic acid are associated with higher risk of hypertension. 
Arachidonic acid may act through changes in eicosanoid and prostaglandin 
metabolism. They also balance between thromoboxan A2 (vasoconstrictor) 
and prostacyclin (vasodilator) . 
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Higher plasma concentration of lipoprotein (a), albeit within normal 
range could be independent risk factor for atherosclerosis and could 
contribute towards, increasing incidence of cardio vascular disease in people 
with essential hypertension
60
. However routine measurement of Lp(a) in 
hypertension should perhaps be simply regarded as research exercise, 
because there is limited data on prognostic and predictive value in 
hypertensive
59
.  
Very few therapeutic manoeuvres can reliably used to lower Lp (a) 
which no clear evidence of benefit perhaps routine lipid profile is more 
appropriate.  
Hyper triglyceridemia in mild hypertension is indicative of insulin 
resistance accompanied by a modified vascular reactivity as well as elevated 
catecholamine and adreno cortico trophic hormone. 
  Hypertriglycerduria in HUCIIITg mice appear to result primarily from 
decreased tissue uptake of triglyceride rich particle from the circulation, 
which is most likely due to increased Apo CIII and decreased Apo E on 
VLDL particles. 
Oxidised LDL cholesterol is vasoconstrictor, mitogenic, pro-
inflammatory and thrombogenic
63
. LDL cholesterol potentiates noradrenalin 
vasoconstriction in the peripheral vasculature and in the coronary, cerebral 
and renal vascular beds
53
. There is also blunting of endothelium dependent 
vasodilator responses to acetylcholine
63
.  
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High Cholesterol has shown in impair endothelium dependent dilation. 
Cholesterol levels influence BP response to adrenergic stimulation as well as 
outcome of target organ disease. Lipoprotein strongly contribute to 
atherogenesis might play a relevant role in pathophysiology of hypertension.  
Total cholesterol is important single blood lipid risk factor for ischemic heart 
disease is men. HDL-cholesterol is less important and triglyceride 
concentration does not have predictive importance once other risk factors 
have been taken its account. 
Similar study showed total cholesterol and triglyceride were positively 
correlated. HDL-cholesterol was inversely correlated with triglyceride. HDL 
cholesterol and total cholesterol were not correlated. There is a strong 
association between apolipoprotein E locus, hypertension and lipid profile. 
Thyroid hormones were reported to be capable of inhibiting atherosclerosis 
in animals and lowering blood cholesterol
56
.  Lipid lowering drug with 
antihypertensive will reduce BP and cardiovascular risk event. Other study 
showed no substantial associated between antihypertensive therapy and 
plasma lipid levels 
64
. 
 NORMAL VALUES OF LIPID PROFILE: 
Triglyceride - 30 -200 mg/dl 
Total cholesterol- 150-200 mg/dl 
LDL- 70-130 mg/dl 
HDL 40-60 mg/dl 
VLDL 20-40 mg/dl 
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URID ACID 
Metabolism:Uric acid is derived from catabolism of 
ingested nucleoproteins  
-endogenous nucleoproteins 
 endogenous purine nucleotides. 
Uric acid is a breakdown product of purine metabolism. It is 
produced in liver and excreted through kidney. Uric acid is completely 
filtered through glomerulus almost fully reabsorbed at proximal convoluted 
tubule and actively secreted along the tubule. Also, catabolised to urea, 
ammonia and finally carbon di oxide. 
Total body content in average adult is 1.2 g 
Plasma uric acid is 3.5 – 7mg/dl in males  
 2.7 – 6.5 mg/dl in females96.  
Average Adult excretes 400 – 600 mg in 24 hrs urine. 
On low purine diet 275 – 600 mg is excreted  
In Gout increase to 18000 – 30000 mg (total content) 
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GOUT:  
Clinical condition, in which uric acid is increased. 
• Primary Gout   -   Ribose Phosphate phosphorylase is deficient. 
• Secondary Gout -   Due to increased purine catabolism seen 
in leukemia, prolong fasting, polycythemia. 
• Renal Gout        -    Uric Acid transport System is affected, 
resulting in failure of excretion. 
• Secondary Renal Gout seen in generalized renal failure106. 
CLINICAL SIGNIFICANCE OF URIC ACID: 
Hyperuricemia is seen in 
 Renal failure  
 Ketoacidosis  
 Lactate Excess  
 Pre eclampsic toxemia with increased lactic acid  
 Diuretics  
Positive relationship of Hyperuricemia to hyperlipidemia is seen in 
following conditions: 
 Obeisty 
 Atherosclerosis 
 Diabetes mellitus 
 hypertension 
 Exercise  
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 Achievement oriented behaviours  
 Diet with high purine like meat, viscera, leguminous vegetable and 
yeast. 
In mammals, uric acid is degraded to allantion by uricase resulting in 
uric acid levels to 0.5 – 1.5 ml/dl, whereas in Hominoids (apes, Humans) 
uric acid level is high due to distinct mutation in uricase gene, that made it  
non-functional. Three mutations are nonsense mutation occurring at codon 
33, a non sense codon 187 and slice mutation inexon 3 .
 
Hypeuricemia occur as a result of either overproduction or under 
excretion of uric acid or both
67
. Over production occur with rare genetic 
disorders. Alcohol consumption, high purine intake, haematological 
malignancies release high purine. Under excretion is clinically significant 
seen in diuretic treated hypertensive.  
Impairment of renal function may cause hyperuricemia through 
reduction in both filtration and secretion of uric acid. Raised S. uric acid can 
be the consequence of an increased urate production, a decreased renal 
excretion or both
69
.  
But studies showed that UA is positively correlated with S.creatinine 
but not in patients with under excretory hyperuricemia.20-40% of patients 
with essential hypertension are hyperuricemic. 
  Uric acid is implicated in pathogenesis of hypertension
74
. There is 
positive relationship of UA to hypertension
72
. 
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 Raise in SBP by 30-40 mmHg will increase UA by 1 mg/dl. 9yrs 
follow up study showed positively associated with incident hypertension and 
UA. This relationship was stronger in Blacks than in whites. 10 yr incidence 
of HTN in a population based cohort study showed positive association 
between UA & hypertension 
A Normative aging study also showed positive relation after adjusting 
for age BMI, abdominal circumference, smoking alcohol ,triglyceride, total 
cholesterol & plasma glucose . 
Mild hyperuricemia was induced in rats by administration of uricase 
inhibitor; they became hypertensive by 3 weeks compared to controls which 
remained normotensive. 
Uric acid induces renal vasocontriction mediated by endothelial 
dysfunction with reduced Nitric acid level and activation of Renin 
Angiotensin System. 
This induces hypertension. In untreated patients with essential 
hypertension raised uric acid is powerful risks marks for subsequent 
cardiovascular disease.  
Uric Acid stimulates vascular smooth muscle cell proliferation 
mediated by stimulation of mitogen-activated protein kinase, 
cyclooxygenase 2, platelet derived growth factor. So elevated uric acid 
predicts severity of Heart failure and need for heart transplantation in 
patients with chronic heart failure. 
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Mild asymptomatic hyperuricemia is associated with decreased renal blood 
flow, without affecting glomerular filtration rate
78
. Increased renal vascular 
and systemic hypertensive vascular disease paralleled the raising S.UA 
levels. These suggest that unexplained hyperuricemia in patients with 
hypertension most likely reflect early renal vascular involvement
79
.Some 
studies showed raise in UA is associated with renal insufficiency but remain 
within normal limit in essential hypertension
80
 . 
The correlation between kidney function & hyperuricemia is present 
if blood urea was over 30 mg %. Hyperuricemia is present over 1/3 of case 
of hypertension, while thiazide administration & renal failure increase 
degree of hyperuricemia. The elevated blood levels are primarily related to 
disease process itself.  
High S. UA & renal failure indicate what was already happened to 
kidney &does not cause mischief of uric acid. Increased sympathetic out 
flow alter renal sodium handling by increasing arterial pressure, decreased 
blood flow and decreased uric acid excretion. This increases S. UA. Raised 
UA increases purine oxidation and reactive 0xygen species and 
Angiotensin+ receptor activation. All these, leads to Hypertensive vascular 
injury.
 
There is positive correlation between S. UA, cholesterol, triglyceride 
and index of body size
106
. But, there is negative correlation between White 
and Blacks whether male or female, but prevalence of HTN was greater in 
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hyperuricemia compared to normouricemics. Annual increment of S.UA in 
hypertensive was related to treatment with methyldopa and not related to 
age, sex, BP control, diuretic therapy or plasma urea.  
High S.UA levels were independently associated with proximal 
tubular sodium reabsorption in men. This relationship suggests an altered 
tubular sodium handling and uric acid metabolism, consistent with 
hyperinsulinemia, insulin resistance being the possible pathophysiological 
link .
.
 Hyperurecemia with untreated hypertension was related significantly 
with alcolhol intake, serum asparate transaminase activity & 
obesity. 
Elevated childhood S. UA is associated with increased blood pressure 
beginning in childhood & higher BP levels that persist in adulthood
84,88
. 
These suggest that Uric acid might have role in early pathogenesis of 
Essential hypertension
87
. Altered lactic acid metabolism in hypertensive 
many account for altered renal transport of uric acid. The changes in kidneys 
are glomerular capillary thickening and sclerosis, tubular atrophy, pigment 
deposits, degeneration in loops of henle and interstitial deposit of uric acid 
in renal medullary tissue. Elevated SUA have linked to 
hypercholesterolemia in normotensive is due to disturbance in lipid 
metabolism.  
S.UA was directly related to BMI, creatinine, triglycericide, LDL 
cholesterol, components of metabolic syndrome and inversely propotional to 
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HDL cholesterol. There is significant association of S.UA with preclinical 
Target organ damage namely LVH, carotid atherosclerosis, 
microalbuminuria, in untreated essential hypertensive patients. regardless of 
other cardiovascular risk factors.  
In vitro, free uric acid was found to increase vascular smooth muscle 
cells, monocyte chemoattractant protein I((MCP I),increased mRNA protein 
expression occurring as early as 3 hrs after uric acid incubation
89
. 
In addition, UA activated the transcription factors kB, activator 
protein I, mitogen activated protein kinase signalling molecule ERK p44/42 
and p38 and increasedcyclooxygenase 2 mRNA expression.  
Hyperuricemia is independent risk factor for CHD, hypertension, 
hyperlipidemia particularly hypertriglyceridemia than with cholesterol, 
Even with treated patients. But recent investigation suggested that 
relationship between raised uric acid & raised cholesterol is largely 
mediated through triglyceride and little association between uric acid & 
HDL cholesterol. 
  The NHANES 1 Epidemiologic follow study showed raised uric acid 
level is independently associated with risk of cardio vascularmortality
90
.  In 
Chicago, peoples gas company study showed association between uric acid 
with prevalence of ECG abnormalities and mortality appeared to be 
secondary to association between uric acid and other risk factors. 
Framingham study showed hyperuricemia is risk factors for CHD even after 
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correcting for hypertension
92
. However in multivariate analysis including 
age, systolic BP, relative weight, cigarette smoking and S. Cholesterol, S. 
Uric acid did not add independently to prediction of CHD. It is linearly 
related CAD severity is women than in men. 
High uric acid is strong independent marker of impaired prognosis 
with moderate chronic heart failure. There is no relation of S. UA with age, 
diet, but there is an increase with bodyweight & body mass. Uric acid has 
direct associated with left ventricular mass index. 
Hyperuricemia was strongly associated with metabolic syndrome and 
also in hypertensive without metabolic syndrome. Uric acid is also strong 
predictor of stroke with myocardial infarction and non-insulin dependent 
diabetes mellitus. 
Isolated Systolic HTN, Serum creatinine and serum uric acid were 
predictors of mortality with CVD and stroke. 
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MATERIALS AND METHODS 
PLACE AND DURATION:  
The current study is done In Tiruneveli Medical College, Department 
of Medicine from our inpatient and outpatient departments from August 
2013 to August 2014. 
INCLUSION CRITERIA: 
Group A comprises of 30 healthy individuals aged between 35-65 years. 
Their BP was recorded < 140/90. 
Group B comprises of 30 hypertensive individuals aged between 35-65 
years and BP was recorded ≥ 140/90 
EXCLUSION CRITERIA: 
 Diabetes mellitus 
 Ischemic heart disease 
 Renal disease 
 History and presence of jaundice 
 Chronic liver disease 
 Familial hyperlipidaemia 
 Patients on lipid lowering drugs 
 Smoking 
 Alcoholics 
 Obese BMI <25 
63 
 
 Gout 
 DATA COLLECTION:  
All these subjects in Group A & Group B were conducted a medical 
examination as per a fixed proforma. Physical examination include 
following anthropometric measurements. 
1) Height: 
  Height was measured by using a vertical board with an attached 
metric scale. The individual was made to stand bare foot on a flat surface 
with weight evenly distributed on both the feet, heel together and head 
positioned so that vision was perpendicular to body. Head, back, buttocks, 
and heels are in contact with vertical board. The headboard was brought in 
contact with the head to compress the hair & the reading recorded to the 
nearest 0.1 cm. 
2) Weight:  
Weight was recorded by making the patient stand on a dial type 
weighing machine with body weight distributed between both feet. 
3) Body Mass Index was calculated using formula 
Weight in Kg / (Height in meter)2. 
 Underweight< 18 
 Normal – 18-24.9 
 Grade I (over weight ) -- 25-29.9 
 Grade II (obese) – 30-39.9 
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 Grade III (very obese) > 40 
4) METHOD OF RECORDING BLOOD PRESSURE:   
Instrument used is sphygmomanometer. It is kept level of heart and cuff 
tied around upper arm.  Systolic pressure is first measured by palpatory 
method and then pressure is raised to 20 mm above the measured systolic 
pressure & then of gradually released. Variation of sound was heard with 
stethoscope placing its chest piece on brachial artery, a little below the cuff. 
The sounds are heard due to occurrence of turbulence in flow of blood 
through the narrow blood vessel, when the manometric pressure just 
coincides with systolic blood pressure.  
When pressure from cuff is released, normal stream line flow sets in & 
sound is no longer heard. This manometric pressure coincides with diastolic 
Blood pressure. As pressure is released, various sounds are heard known as 
Korokoff sounds. 
 Phase I-sudden appearance of tapping round persist 
for 15 mmHg. This indicates systolic pressure. 
 Phase II – murmur persist for another 15 mm Hg. 
 Phase III – clear loud gong sound for 20mm Hg. 
 Phase IV – muffled & fading sound. This indicate diastolic pressure. 
BP is recorded 3 times at 30 min interval and mean BP is taken. 
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BIOCHEMICAL TESTS: 
Morning sample blood was drawn after 12 hrs fasting. The samples of 
blood were allowed to stand to clot. Precautions were taken so that the blood 
did not haemolyse. Serum was separated by centrifugation. and analysed by 
the following methods. 
METHODOLOGY: 
Calorimetric, enzymatic method with glycerophospate oxidase. This 
reagent is based on the method of wako and the modifications by Mc Gowan 
et al and Fossati et all. 
PRINCIPLE: 
Triglycerides +H2O glycerol + free fatty acids 
Glycerol + ATP  Glycerol 3 phosphate + ADP 
Glycerol 3 phosphate + O2 DAP + H2O2 
H2O2 + 4AAP +3,5DHBS  Quinoneimine dye + 2H2O 
The intensity of quinoneimine formed is proportional to the triglycerides 
concentration in the sample when measured at 505 nm(500-540nm) 
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PROCEDURE: 
Pippette in tubes 
marked 
blank Standard Test 
Working reagent 1000 ul 1000ul 1000ul 
Distilled water 10ul - - 
Standard - 10ul - 
Sample - - 10ul 
 
Mix and incubate for 10 minutes at 37 degree c, read the absorbance 
of standard and each sample at 505/670 nm on biochromatic analysers 
against reagent blank. 
CALCULATION: 
Triglycerides (mg/dl) = abs of test/abs of standard * concentration of 
std (mg/dl). 
CHOLESTEROL: 
METHODOLOGY: 
The method is based on the Trinders methodology 
PRINCIPLE: 
Cholesterol ester + H2O  Cholesterol + fatty acids 
Cholesterol + O2 Cholest-4-en-3-one + H2O2 
2H2O2 + 4AAP + Phenol  Quinoneimine dye + 4H2O 
Absorbance of Quinoneimine so formed is directly proportional to 
cholesterol concentration. 
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PROCEDURE: 
Pippette in tubes 
marked 
blank Standard Test 
Working reagent 1000 ul 1000ul 1000ul 
Distilled water 10ul - - 
Standard - 10ul - 
Sample - - 10ul 
 
Mix well and incubate for 5 minutes at 37 degree c or 10 minutes at 
20 -25 degree c. read the absorbance of the test and standard against reagent 
blank. 
CALCULATION: 
Cholesterol (mg/dl) = abs of test/abs of standard * concentration of std 
(mg/dl). 
HDL DIRECT: 
The assay is based on a modified polyvinyl sulfonic acid and 
polyethylene glycol methyl ether coupled classic precipitation method with 
the improvements in using optimised quantities of PVS/PEGME and 
selected detergents. LDL, VLDL and chylomicron react with PVS and 
PEGME and the reaction results in the inaccessibility of LDL, VLDL and 
chylomicron by cholesterol oxidase and cholesterol esterase. The enzymes 
selectively react with HDL to produce H2O2 which is detected through a 
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trinder reaction. 
HDL + LDL+VLDL+CM  HDL +(LDL+VLDL+CM) + PVS/PEGME 
HDL  fatty acid + H2O2 
2H2O2 + 4-AA +TODB  Quinone +5H2O 
SERUM URIC ACID: 
METHODOLOGY: 
The reagent is based on trinders reaction, enzymatic and colorimetric 
method. 
PRINCIPLE : 
Uric acid + O2 +H2O  ALLANTOIN + CO2 + H2O2 
TOOS + 4AAP + 2H2O2 Quinoneimine dye + 4H2O 
The intensity of colour formed is proportional to the uric acid concentration. 
PROCEDURE: 
Pippette in tubes 
marked 
blank Standard Test 
Working reagent 1000 ul 1000ul 1000ul 
Distilled water 10ul - - 
Standard - 10ul - 
Sample - - 10ul 
 
Mix and incubate for 5 minutes at 37 degree c, read the absorbance 546/670 
nm on barometric analysers against reagent blank. 
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CALCULATIONS: 
Uric acid = abs of test/abs of standard * concentration of std (mg/dl). 
VLDL = Triglyceride/ 5 
LDL = Total cholesterol – (HDL +VLDL) by Freidewelds formula 
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OBSEVATION &RESULTS 
STATISTICAL ANALYSIS 
STUDY DESIGN 
 A Case –control study consisting of 30 controls and 30 cases is 
undertaken to study the relationship between serum uric acid and lipid 
parameters 
STATISTICAL ANALYSIS 
The information collected regarding all the selected cases were 
recorded in a Master Chart.  
The range, frequencies, percentages, means, standard deviations, chi 
square, „t‟ value and  'p'  values were calculated. 
Student‟s „t‟  test was used to test the significance of difference 
between quantitative variables . 
Yate‟s and Fisher‟s chi square tests for qualitative variables. 
A 'p' value less than 0.05 is taken to denote significant relationship. 
SIGNIFICANT FIGURES: P VALUE 
  Suggestive significance 0.05<P<0.10 
 Moderately significant 0.01<P ≤ 0.05 
Strongly significant P≤0.01 
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RESULTS: 
TABLE 8: AGE DISTRIBUTION 
 
Age Group 
Hypertensive Group Control Group 
No % No % 
35 – 45 yrs 8 26.7 9 30 
46 – 55 yrs 10 33.3 12 40 
56 – 65 yrs 12 40 9 30 
Total 30 100 30 100 
Range 36 – 64 yrs 36 – 64 yrs 
Mean 50.8 yrs 50.4 yrs 
SD 8.5 yrs 8.6 yrs 
„p‟ 0.88 Not Significant 
 
The individuals selected for both cases and controls are categorized 
age wise  and stratified into three age categories and looked for any specific 
increase in the blood pressure, serum lipid profile and serum uric acid. 
Using the table it is calculated that the mean age of hypertensive cases 
is about 50.8 years and in controls it is about 50.4 years. 
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The distribution of cases and controls is equal among different age groups 
All cases have blood pressure > 140/90 mmhg 
All controls have blood pressure <140/90mmhg 
 
 
 
 
FIGURE 9: AGE DISTRIBUTION IN HYPERTENSIVE CASES 
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.FIGURE 10 : Mean age in hypertensive and control group 
 
So the number of hypertensive were more in the age group of 55to 65 years 
in comparison with the age in the hypertensive cases. 
The mean age in the hypertension group is calculated about 50.8 
years.    The distribution of cases and controls is equal between controls and 
cases and so the „p‟ value is statistically not significant. 
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FIGURE 11: Age group wise blood pressure elevation 
 
The diagram shows the age wise elevation of blood pressure. 
Of the hypertensive population, elevation of blood pressure is higher 
in the age group of 55 to 65 years, since arteriosclerosis and vascular 
changes contribute more to them. 
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TABLE 9: AGE GROUP AND BLOOD PRESSURE ELEVATION 
 
Age Group 
Blood pressure in Hypertensive group 
 
Systolic B.P. Diastolic B.P. 
Mean SD Mean SD 
35 - 45 147.3 2.4 100.0 0.0 
46 – 55 158.2 6.0 102.2 4.2 
56 - 65 170.2 4.0 105.8 5.3 
„p‟ <0. 0001 Significant 0.0133 Significant 
 
The table shows blood pressure elevation is seen more in the age 
group of 55 to 65 years. 
„P‟ value is significant indicating that there is a significant correlation 
relating the age group and blood pressure elevation. 
Both systolic blood pressure and diastolic pressure tend to show 
correlation with the age group. 
„P‟ value is significant in both hypertensive and control population. 
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TABLE 10: SEX DISTRIBUTION 
 
Group 
Sex 
Male Female 
No % No % 
Hypertensive 15 50 15 50 
Control 15 50 15 50 
„p‟ 1.0 Non Significant 
 
 
The sex distribution is equal between cases and controls. 
    Both in hypertensive cases and also in the controls, both men and 
women were equally distributed for an effective and comparison. 
     The table shows that the „p‟ value calculated is statistically not 
significant. 
 
 
 
 
 
 
 
77 
 
 
 
 
 
FIGURE 12: Sex distribution in hypertensive and control 
 
The bar diagram shows there is an equal distribution sex both in case 
and control population. 
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BMI, HEIGHT AND WEIGHT IN STUDY POPULATION 
 
FIGURE 13: BMI, Height, and Weight in study population 
The heights, weight of the individuals were measured and BMI 
calculated and obese individuals were excluded from the study by the fixed 
criteria. 
The mean values calculated for both hypertensive cases and controls 
were shown in the diagram. 
The mean BMI for hypertensive cases is 23.2 and for cases it is 22.9. 
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PULSE RATE: 
 
 
FIGURE14: Mean pulse rate in hypertensive and controls 
 
 The pulse rate measured for both the hypertensive cases and in the 
control group was found to be in normal range with no variation. 
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TABLE 11: BLOOD PRESSURE 
 
Group 
Systolic B.P Diastolic B.P 
Range Mean SD Range Mean SD 
Hypertensive 144 - 178 160.1 10.4 96 – 112 103.1 4.7 
Control 110 - 130 120.1 7.6 78 – 84 80.1 0.9 
„p‟ <0.0001 Significant                    <0.0001 Significant 
 
 
The blood pressure for both the hypertensive cases and controls were 
plotted and mean blood pressure for both the study population obtained. 
All the hypertensive cases have blood pressure > 140/90mmhg. 
All the controls have blood pressure <140/90mmhg 
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SYSTOLIC AND DIASTOLIC BLOOD PRESSURE IN STUDY 
POPULATION 
 
 
 
FIGURE15: Mean systolic and diastolic bp in study population 
 
The mean systolic and diastolic blood pressure measure in the 
hypertensive cases is about 160 and 103 respectively. 
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DYSLIPIDEMIA  
TABLE12: TRIGLYCERIDE 
Group 
 
Triglyceride 
Normal Abnormal 
Range Mean SD 
 No % No % 
Hypertensive 8 26.7 22 73.3 
 
118 - 294 219.2 42.3 
Control 27 90 3 10 
 
78 - 224 125.1 39.1 
„p‟ <0.0001 Significant                    
 
The triglyceride levels were found to be elevated in hypertensive 
cases, when compared to controls.  
The „p‟ value is <.001, which is   significant denoting the correlation 
in hypertensive cases, when compared to controls. 
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FIGURE16: Mean triglyceride levels 
 
 
 
 
The mean triglyceride level found in hypertensive cases is 219.2. In 
control population, the mean value is 125. 
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TABLE 13: TOTAL CHOLESTEROL 
 
Group 
 
Total Cholesterol 
Normal Abnormal 
Range Mean SD 
 No % No % 
Hypertensive 7 23.3 23 76.7 
 
180 – 316 249.7 42.0 
Control 28 93.3 2 6.7 
 
120 – 224 160.1 25.3 
„p‟ <0.0001 Significant                    
 
 
The total cholesterol values were also observed to be elevated in 
hypertensive cases.  
In control population, only few individuals have elevated total 
cholesterol values. 
The „p‟ value is<.001 which is significant correlating the relation in 
hypertensive cases, when compared to controls. 
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FIGURE 17: Mean cholesterol values. 
 
The mean total cholesterol value in hypertensive is 242 mg/dl and in 
controls, it is 160mg/dl. 
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TABLE14: LDL 
 
The LDL levels were elevated in hypertensive group, when compared 
to control population.  
The „p‟ value is <.0001, which is significant showing the correlation 
of elevated LDL level in hypertensive population. 
 
 
 
 
Group 
 
LDL 
Normal Abnormal 
Range Mean SD 
 No % No % 
Hypertensive 9 30 21 70 
 
48 - 259 158.6 50.2 
Control 28 93.3 2 6.7 
 
50 - 180 90.1 28.5 
„p‟ <0.0001 Significant                    
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FIGURE18: Mean LDL levels 
 
 
 The mean LDL level in hypertensive cases is 158   
And in control group, the mean value is 90. 
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TABLE15: VLDL 
 
Group 
 
VLDL 
Normal Abnormal 
Range Mean SD 
 No % No % 
Hypertensive 10 33.3 20 66.7 
 
28 - 65 45.6 8.6 
Control 27 90 3 10 
 
14 - 50 26.7 8.8 
„p‟ <0.0001 Significant                    
 
 
The VLDL levels were elevated in hypertensive cases in comparison 
with the control population. 
The „P‟ value is <0.0001, which is statistically significant showing the 
elevation of VLDL levels in hypertensive population. 
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FIGURE 19: MEANVLDL LEVELS 
 
 
 
 
 The mean VLDL in hypertensive cases is 45.6. 
And in control group, it is 26.7. 
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TABLE 16: HDL 
Group 
 
HDL 
Normal Abnormal 
Range Mean SD 
 No % No % 
Hypertensive 12 40 18 60 
 
23 - 68 37.7 9.6 
Control 29 96.7 1 3.3 
 
36 - 80 53.7 10.5 
„p‟ <0.0001 Significant                    
 
 
The HDL levels were observed to be decreased in hypertensive population, 
when compared to controls. 
The „P‟ value is<.0001, which is statistically significant showing the 
correlation of decreased levels of HDL in hypertensive population. 
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FIGURE 20: Mean HDL levels 
 
 
 
 
The mean value of HDL in hypertensive cases is 37.7 
And in control group, it is 53.7. 
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TABLE 17: DYSLIPIDAEMIA 
 
Group 
Dyslipidaemia 
 
Present Absent 
 No % No % 
Hypertensive 24 80 6 20 
Control 7 23.3 23 76.7 
„p‟ <0.0001 Significant                    
 
 
 
The lipid parameters as a whole, or as an individual parameter elevation is 
seen mostly in hypertensive cases, when compared with controls. 
The „P‟ value is statistically significant showing the correlation of elevation 
in hypertensive population when matched with the control population  
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DYSLIPEDEMIA 
FIGURE 21: Dyslipidemia in hypertensive and control group 
 
The elevation of triglyceride, total cholesterol, LDL,VLDL  or as an 
individual parameter elevation is seen about 24 individuals in hypertensive 
cases, where as in the control population it is only about 6 cases , mostly of 
which is elevated triglyceride levels. 
   This clearly shows that the hypertensive population has been 
associated with the elevation of lipid parameters, in comparison with the 
control population. 
94 
 
FIGURE 22: Age and dyslipedemia 
 
In the hypertensive population, more occurrence of dyslipidemia is 
seen in the age group of 55 to 65 years. 
Since the severity of BP elevation is more in age group 55 to 65 year 
age group, dyslipidemia is more seen in the age group 55 to 65 year age 
group. 
Thus it also implies that dyslipidemia is also related with severity of 
elevation of BP and it can also be age related. 
CONTROL GROUP 
HYPERTENSIVE CASES 
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TABLE 18: SERUM URIC ACID 
 
Serum uric acid levels are observed to be elevated in most of the 
hypertensive population, where as in control population, no elevation of uric 
acid is observed. 
25 cases of hypertensive cases have found to be increased levels of 
uric acid from its normal value.  
Group 
 
Serum Uric Acid 
Normal Abnormal 
Range Mean SD 
 No % No % 
Hypertensive 5 16.7 25 83.3 
 
6.3 – 9.8 
7.89 0.91 
Control 30 100 - - 
 
4.2 – 5.6 
5.0 0.44 
„p‟ <0.0001 Significant                    
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FIGURE23: Mean serum uric acid level 
 
 
The serum uric acid levels found to be elevated in most of the hypertensive 
cases in comparison to the control population. 
This clearly depicts the correlation of elevation of serum uric acid with 
hypertension. In control population, no uric acid elevation is seen. 
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TABLE19: HYPERURICEMIA 
 
Group 
Hyperuricemia 
 
Present Absent 
 No % No % 
Hypertensive 25 83.3 5 16.7 
Control - - 30 100 
„p‟ <0.0001 Significant                    
 
In hypertensive cases, 25 cases have shown elevation of serum uric acid, and 
no controls have shown the elevation of uric acid. 
In hypertensive cases, „P‟ value is significant denoting the vital correlation 
between the elevation of uric acid in hypertensive population. 
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FIGURE24: Hyperuricemia 
 
 
FIGURE 
This diagram shows the number of hypertensive individuals showing the 
elevation of uric acid. 
The control group does not show any elevation of uric acid. 
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BLOOD GLUCOSE: 
 
 
 
FIGURE25: Mean blood glucose level 
 
Diabetic patients have been excluded from the study population .The 
diagram shows normal value of blood sugar in both hypertensive and control 
population 
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SERUM UREA AND CREATININE: 
 
FIGURE 26: Mean serum urea level 
 
 
FIGURE 27: Mean serum creatinine level 
Renal disease is excluded from the study population. 
Serum urea and creatinine values are normal both in hypertensive 
cases and control population 
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TABLE 20:  DYSLIPIDAEMIA AND HYPERURICEMIA 
 
Dyslipidaemia 
Hypertensive Group Controls Group 
Hyperuricemia Hyperuricemia 
Present Absent Present Absent 
No % No % No % No % 
Present 24 100 - - - - 7 100 
Absent 1 16.7 5 83.3 - - 23 100 
„p‟ <0.0001 Significant -- 
 
In the hypertensive group, most of the individuals, about 80% have 
dyslipidemia and are associated with increased level of serum uric acid. 
    In the control population, dyslipidemia is seen only in around 20% of 
population and in them also, serum uric acid level is not elevated. 
   The „P‟ value is significant implying the correlation of relationship 
between serum uric acid and dyslipdemia in hypertensive cases, where as in 
controls no such relation is seen. 
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FIGURE 28: Dyslipedemia and hyperuricemia 
In hypertensive population, most of the individual have dyslipidemia and 
they are associated with elevation in serum uric acid. 
Even elevation in any one of the lipid parameter is associated with elevation 
in serum uric acid. In control population, only few of them has dyslipedemia 
and in them also, no elevation of serum uric acid is observed. 
   This demonstrates the correlation of dyslipidemia and uric acid in essential 
hypertension
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DISCUSSION 
1. AGE AND BLOOD PRESSURE ELEVATION 
Blood pressure elevation is observed as the age group increases. As 
age increases, a rise in blood pressure elevation is observed. 
The level of blood pressure rise is observed more in 55-65 year age 
group. 
Also more number of hypertensive are observed in 55-65 age group. 
Blood pressure rises with age and this rise is observed more in age 
group 55-65 years age group and this shows the blood pressure elevation is 
associated with rise in age group. 
TABLE 8, 9 shows the relation between age group and hypertension.  
FIGURE 9,10,11 age distribution in hypertensive cases, mean age in 
hypertensive and control group and age group wise blood pressure elevation 
respectively. 
2. DYSLIPIDEMIA AND HYPERTENSION 
An elevated level of triglycerides, LDL, VLDL and decreased level of 
HDL is observed more in hypertensive group. Most of the individuals in 
hypertensive group has elevation of lipid parameters as a whole or rise in 
any one of the individual lipid parameter, excluding HDL. 
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About 24 out of 30 cases in the hypertensive group has observed to 
have dyslipidemia ,either as total increase in all  lipid parameters or increase 
in any one of the  lipid parameter ,excluding HDL. 
In control population only few of the individuals have dyslipidemia, 
most of the control population do not have any lipid abnormality. Only 4 of 
30 have increased triglycerides and 2 of them have increased cholesterol 
levels . 
So, about 80% of hypertensive population have dyslipidemia. 
In control population, only 20% have dyslipidemia and they too have 
only increased triglyceride levels. 
Also the rise in lipid parameters is more with age group, more seen in 
55-65 years age group and the elevation also increases with increase in blood 
pressure. 
The proportion and also magnitude of dyslipedemia both increases 
with age and blood pressure  
This implies that  dyslipedemia  shows a direct relationship with both 
increase in age and has correlation with elevation in blood pressure. 
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TABLE 12,13,14,15 shows the „P‟ value is statistically significant 
denoting the correlation of rise of triglyceride, total cholesterol, LDL, VLDL 
with hypertension.  
FIGURE 16,17,18,19 shows mean triglyceride, cholesterol, LDL, 
VLDL levels in both study population and it is observed that there is an 
elevation of triglyceride, cholesterol, LDL, VLDL in hypertensive group, 
when compared with control population.  
TABLE 16 shows the „P‟ value is statistically significant showing the 
decrease in HDL is significant in essential hypertensive.  
FIGURE 20 shows the observed decreased mean HDL levels in 
hypertensive group compared to control group.  
TABLE 17 shows most individuals in hypertensive group have 
dyslipidemia, compared to controls who have only few individuals with 
triglyceride elevation.  
FIGURE 21 shows 80 % of hypertensive group have dyslipidemia and 
20% of control population have triglyceredemia. 
3. SERUM URIC ACID AND HYPERTENSION: 
Uric acid elevation is seen in most of the individuals in hypertensive 
group. About 25 of 30 people have elevation of serum uric acid and its 
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elevation is directly proportional to rise in blood pressure. This implies that 
serum uric acid level is an independent risk factor in hypertension and its 
level also correlates with the severity of hypertension. 
Uric acid level is not elevated in control group. 
This shows that uric acid elevation is seen in hypertensive group and 
not in control. 
TABLE 18 shows „P‟ value is statistically significant denoting the 
correlation of elevation of serum uric acid in essential hypertension.  
FIGURE 23 shows serum uric acid elevation in hypertensive group, 
where as in control population serum uric acid is not elevated.  
TABLE 20 shows „P‟ value is statistically significant denoting the 
correlation of elevation of serum uric acid with dyslipidemia.  
FIGURE 28 shows the elevation of serum uric acid in hypertensive 
group with dyslipidemia, where as in controls even with dyslipidemia ,serum 
uric acid is not elevated.  
4 .DYSLIPEDEMIA AND URIC ACID ELEVATION: 
Dyslipedemia is seen in most of the hypertensive cases. About 24 out 
of 30 cases has elevation in lipid parameters. About 80% of study population 
have elevated dyslipidemia observed. 
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In all hypertensive individuals with elevated lipid parameters, it is 
observed that the serum uric acid level is elevated. The serum uric acid 
elevates, either with rise in all of lipid parameters or if any one of the lipid 
parameter is elevated, excluding HDL. 
The rise in serum uric acid is also proportional to the severity of 
hypertension and also with the age group. 
In control population, serum uric acid level is not elevated. 
In control population, only few have dyslipidemia. About 6 of 30 
individuals have dyslipidemia and they too have elevated triglycerides and 
total cholesterol values alone. Even in those individual with dyslipidemia, 
serum uric acid level is not elevated. 
This implies that dyslipidemia is associated with elevation of serum 
uric acid in hypertensive group, where as in control group dyslipedemia is 
not associated with elevation of serum uric acid. 
This clearly denotes the correlation of serum uric acid and 
dyslipidemia in essential hypertension 
Dyslipidaemia in hypertension is due to lipid deposition in lumen of 
arterial wall, causing atherosclerosis. This increases the resistance to flow of 
blood in blood vessel, causing hypertension. HDL-Cholesterol impairs 
endothelium dependent dilation. HDL-cholesterol is a protective factor 
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decreased in hypertensive, suggesting more risk of developing complication 
of hypercholesterolemia
92
. High cholesterol influence adrenergic stimulation 
and outcome of target organ damage is more in hypertensive.  
LDL-cholesterol is vasoconstrictor, mitogenic, proinflammatory and 
thrombogenic. So its raise in hypertensive is a risk for developing 
complications.  
Hypertension is a degenerative process, taking place in blood vessels 
affecting blood supply to target organs like Heart, Kidney and Liver. 
Damage to these organs is called Target Organ Damage
108
. These 
degenerative process increases purine metabolism also, rising uric acid 
levels. 
In hypertension, there is enhanced proximal tubular reabsorbtion and 
depressed tubular secretion of uric acid causing hyperuricemia. Diuretic 
treatment of hypertension will also cause hyperuricemia. Hyperuricemia is 
present in 1/3 rd cases of hypertension and increased in thiazide treatment. 
Uric acid is an independent risk factor for atherosclerosis. . Uric acid 
excretion is affected by kidney due to decreased renal perfusion in 
hypertension.  
Hypertension complication like CCF, Heart failure has more 
endothelial dysfunction due to dyslipidaemia and raised uric acid.  
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So in all hypertensive, dyslipidaemia and serum uric acid is correlated. 
Detection of this correlation at an early stage will prevent complications of 
hypertension. 
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CONCLUSION 
    Dyslipidemia is seen in essential hypertensive individuals. 
    Elevation of triglycerides, rise in total cholesterol, raised LDL and 
raised VLDL is observed in Essential hypertensive individuals. The levels of 
HDL are observed to be low in Essential hypertensive individuals. 
     Elevation of serum uric acid level is seen in essential hypertensive. 
Both dyslipidaemia and hyperuricemia observed to be elevated with increase 
in age in essential hypertensive. 
     In normotensives, few have elevated triglyceride levels and elevated 
total cholesterol levels. Though hypertriglyceridemia increase as age 
increase, it is not associated with hyperuricemia.  
This concludes that dyslipidaemia is correlated to hyperuricemia in 
essential hypertensive and not in normotensive. 
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ANNEXURES  
 
 
ANNEXURE - I 
A PROSPECTIVE STUDY OF CORRELATION BETWEEN 
SERUM URIC ACID AND DYSLIPIDEMIA IN ESSENTIAL 
HYPERTENSION 
 
PROFORMA 
 
Case No:                                                                                                           Date : 
 
Name of the patient: 
Age: 
Sex: 
Hospital no: 
Address: 
 
Complaints: 
 
Past History: 
Diabetes mellitus 
Hypertension 
Ischemic Heart disease 
Lung disease 
Thyroid disease 
Renal disease 
Liver disease 
Any other illness 
 
 
 
Drug History: 
Diuretics 
Lipid lowering agents: 
Steroids 
Others 
Personal History: 
Diet 
Smoking 
Alcohol 
Family History: 
Cardiovascular disease 
Hypertension  
Hyperlipidemia: 
Other 
GENERAL PHYSICAL EXAMINATION: 
Built 
Height 
Weight 
BMI 
Nutrition 
Pallor 
Icterus 
Clubbing 
Oedema 
Cyanosis 
 
 
Lymphadenopathy 
Thyromegaly  
VITALS: 
BP (At 30 min interval) 1.                  2.                         3. 
Pulse 
Respiratory rate: 
SYSTEMIC EXAMINATION: 
1. Respiratory System 
2. Cardiovascular System 
3. Abdominal System 
4. Nervous System 
INVESTIGATIONS: 
1. Serum Triglyceride                       mg/dl 
2. Serum Cholesterol                       mg/dl 
3. Serum VLDL                                mg/dl 
4. Serum HDL                                  mg/dl 
5. Serum LDL                                  mg/dl 
6. Serum Uric acid                          mg/dl 
7. Blood glucose                             mg/dl 
8. Serum urea                                 mg/dl 
9. Serum creatinine                         mg/dl                              
 
 
 
 
 
 
 
 
 
ANNEXURE II – MASTER CHART 
Group S.NO NAME AGE SEX HEIGHT WEIGHT PULSE RATE/MIN SBP DBP TRIGLYCERIDES TOAL  CHOLESTEROL LDL VLDL HDL SERUM URIC ACID BLOOD GLUCOSE SERUM UREA CREATININE
HYPERTENSIVE 1 KOMBUDEVAR 58 MALE 170 68 72 172 110 272 257 155 54 48 8.9 120 20 0.8
HYPERTENSIVE 2 RAMACHANDRAN 36 MALE 172 66 74 144 100 138 180 110 28 42 6.9 130 18 0.7
HYPERTENSIVE 3 MURUGAN 46 MALE 172 59 73 156 100 176 206 129 35 42 7.9 110 24 0.9
HYPERTENSIVE 4 GANESAN 64 MALE 169 67 74 172 110 226 300 225 45 30 9 124 16 1
HYPERTENSIVE 5 GEORGE MATHEW 57 MALE 168 65 72 168 112 276 266 166 55 45 9.2 134 18 0.8
HYPERTENSIVE 6 SAMU 61 MALE 174 62 78 176 112 270 290 202 54 34 8.9 124 22 0.8
HYPERTENSIVE 7 MUTHUSAMY 52 MALE 173 68 72 162 100 257 275 168 51 56 7.6 114 24 0.8
HYPERTENSIVE 8 SAHID ALI 38 MALE 171 59 74 148 100 168 184 118 34 42 6.9 112 26 0.8
HYPERTENSIVE 9 JOHN ABRAHAM 58 MALE 168 65 76 178 100 294 281 184 59 38 9.6 124 18 0.7
HYPERTENSIVE 10 PAULRAJ 40 MALE 166 63 78 146 100 196 198 119 39 40 6.9 126 26 1
HYPERTENSIVE 11 ANTHONY 56 MALE 170 68 72 168 108 212 290 225 42 23 8.1 132 16 0.8
HYPERTENSIVE 12 ANNAMALAI 44 MALE 172 68 74 152 100 232 239 154 47 38 7.8 123 18 0.8
HYPERTENSIVE 13 MUBARAK ALI 63 MALE 169 66 72 170 100 241 293 214 48 31 8.4 102 24 0.8
HYPERTENSIVE 14 CHELLAIH 54 MALE 170 68 71 160 110 216 206 129 43 34 7.8 106 26 1
HYPERTENSIVE 15 SUDALAI 42 MALE 172 67 75 148 100 227 198 112 44 42 7.9 112 22 0.6
HYPERTENSIVE 16 GNANAM 46 FEMALE 165 58 76 152 100 232 244 164 46 34 7.8 118 24 0.8
HYPERTENSIVE 17 BHATHRAKALI 39 FEMALE 172 66 72 146 100 118 194 126 23 45 6.3 126 26 0.8
HYPERTENSIVE 18 GANDHIMATHI 48 FEMALE 160 64 74 162 104 212 232 155 42 35 7.6 130 24 0.9
HYPERTENSIVE 19 MULAKIAMMAL 51 FEMALE 168 55 76 166 100 265 255 168 53 34 7.9 124 28 0.7
HYPERTENSIVE 20 KALYANI 41 FEMALE 166 62 78 146 100 196 184 100 39 45 6.4 116 24 0.8
HYPERTENSIVE 21 ALAGARASI 54 FEMALE 164 61 71 158 100 208 278 205 41 32 7.8 106 18 0.9
HYPERTENSIVE 22 POKKODI 62 FEMALE 166 64 72 170 110 226 284 215 45 24 9.8 112 20 0.8
HYPERTENSIVE 23 GAJALAKHMI 58 FEMALE 162 59 74 168 108 268 252 162 54 36 8.6 108 22 0.8
HYPERTENSIVE 24 MUNIYAMAL 47 FEMALE 165 66 76 156 106 216 221 146 43 32 7.9 124 24 1
HYPERTENSIVE 25 LOGAMBAL 56 FEMALE 162 57 78 166 100 221 286 214 44 28 8.2 128 26 0.7
HYPERTENSIVE 26 VIJAYA 37 FEMALE 161 64 74 148 100 157 188 89 31 68 7.8 118 24 0.6
HYPERTENSIVE 27 NALLAMAI 59 FEMALE 158 72 72 170 100 210 316 244 42 30 9.2 114 22 0.8
HYPERTENSIVE 28 PARVATI 57 FEMALE 160 68 72 164 100 257 272 183 51 38 7.8 118 20 0.8
HYPERTENSIVE 29 RANI 53 FEMALE 162 59 71 164 106 223 297 226 44 27 7.8 110 18 0.8
HYPERTENSIVE 30 SENTHAMARAI 46 FEMALE 164 59 72 146 96 167 296 220 33 43 7.8 124 16 0.8
CONTROL 31 PALANIAPAN 38 MALE 170 68 72 124 80 110 152 62 22 68 5 120 22 0.8
CONTROL 32 SITTHIQ 48 MALE 168 65 74 120 80 108 136 50 22 64 5.2 130 20 0.6
CONTROL 33 ALAGU NAMBI 36 MALE 167 66 72 112 80 120 194 130 24 40 4.2 124 18 1
CONTROL 34 RAMA SUBBU 54 MALE 172 70 78 110 80 120 170 86 24 60 4.2 112 16 0.8
CONTROL 35 VASUDEVAN 58 MALE 165 64 74 130 80 122 142 76 24 42 4.6 126 24 0.7
CONTROL 36 KUPPUSAMY 64 MALE 164 62 72 130 80 224 158 70 46 42 5.6 106 28 0.9
CONTROL 37 MALAIAPPAN 44 MALE 169 65 74 120 80 124 194 119 25 50 5.2 112 16 0.8
CONTROL 38 MADHAYAN 46 MALE 172 68 76 110 80 106 160 95 21 44 4.6 108 22 1
CONTROL 39 VEERASAMY 61 MALE 170 68 72 120 80 110 214 128 22 54 5.2 124 18 0.8
CONTROL 40 ALEX MATHEW 56 MALE 168 67 74 110 80 126 164 79 25 60 4.8 126 28 0.8
CONTROL 41 SIRAJUDDIN 62 MALE 167 64 78 130 80 124 180 112 25 43 5.2 128 14 0.9
CONTROL 42 MANAVALAN 51 MALE 169 68 72 120 80 120 171 80 24 67 4.4 124 18 1
CONTROL 43 MOHAMMED ABDULLA 41 MALE 165 62 72 110 80 90 134 66 18 50 4.6 126 22 0.8
CONTROL 44 VETRIVEL 53 MALE 164 63 74 130 80 124 190 113 25 52 5.2 132 16 0.9
CONTROL 45 KANDASAMY 64 MALE 168 64 74 124 84 200 170 94 40 36 4.8 112 28 0
CONTROL 46 MARISELVAM 46 FEMALE 170 68 76 110 80 120 160 90 24 46 4.2 114 32 0.7
CONTROL 47 INDUMATHI 38 FEMALE 172 66 72 126 80 124 156 71 25 60 4.9 112 16 0.6
CONTROL 48 TAMIL ARASI 51 FEMALE 168 65 72 130 80 132 149 80 27 42 5.2 108 26 0.8
CONTROL 49 FATHIMA 42 FEMALE 165 62 74 120 80 142 154 72 28 54 5.6 118 14 1
CONTROL 50 UMAIYAMMAL 53 FEMALE 167 64 78 110 80 112 160 82 22 56 5.2 120 18 0.8
CONTROL 51 SAHMIMA BEGUM 44 FEMALE 168 62 72 120 80 130 152 74 26 52 4.8 124 22 0.8
CONTROL 52 VAIRAM 54 FEMALE 170 68 74 110 80 100 156 82 20 54 5.6 126 24 0.8
CONTROL 53 VIJAYA LAKSHMI 49 FEMALE 172 70 74 126 78 120 140 74 24 42 5.2 118 22 1
CONTROL 54 AJITHA 41 FEMALE 169 68 72 110 80 78 150 68 16 66 4.8 108 24 0.6
CONTROL 55 ESAKITHAI 62 FEMALE 168 64 74 120 80 210 168 80 42 42 4.8 104 18 0.6
CONTROL 56 VALLIAMMAL 51 FEMALE 165 64 76 130 80 124 140 73 25 42 5.6 114 28 0.8
CONTROL 57 ALEINA 39 FEMALE 172 68 78 120 82 78 180 110 16 54 5.4 126 24 1
CONTROL 58 CATHERINE 64 FEMALE 170 64 72 130 80 150 220 124 30 66 5.6 124 18 0.8
CONTROL 59 ARULARASI 47 FEMALE 168 67 74 120 80 80 198 132 16 50 4.8 124 16 0.9
CONTROL 60 ANBALAGI 56 FEMALE 167 66 72 120 80 220 190 104 44 42 5.6 126 22 0.8
 
 
ANNEXURE III 
KEY TO MASTER CHART 
Group 
Hypertensive, control 
Sex 
Male, female 
BMI 
 Underweight < 18 
 Normal – 18-24.9 
 Grade I (over weight ) -- 25-29.9 
 Grade II (obese) – 30-39.9 
 Grade III (very obese) > 40 
 
BLOOD PRESSURE 
HYPERTENSIVE - Systolic blood pressure >140mmhg, 
                                   Diastolic blood pressure >90mmhg 
CONTROL            - Systolic blood pressure <140mmhg, 
                                  Diastolic blood pressure <90mmhg 
 
 
 
 
 
 
 
 
SERUM LIPID PROFILE – NORMAL VALUES 
TRIGLYCERIDE                   - 30 to 200 MG/DL 
TOTAL CHOLESTEROL    - 150 to 200 MG/DL 
LDL                                          - 70 to130 MG/DL 
HDL                                         - 40 to 60 MG/DL 
VLDL                                      - 20 to 40 MG/DL 
 
SERUM URIC ACID – NORMAL VALUES 
MALE        -   3.5 to 7 MG/DL  
FEMALE  -   2.7 to  6.5 MG/DL . 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE – IV 
LIST OF ABBREVIATIONS USED 
BP – Blood Pressure 
 
JNC- Joint National Committee 
 
LDL- Low Density Lipoprotein 
 
HDL- High Density Lipoprotein 
 
VLDL- Very Low Density Lipoprotein 
 
CCF- Congestive cardiac failure 
 
HTN- Hypertension 
 
CHD- Coronary Heart Disease 
 
SBP- Systolic Blood Pressure 
 
DBP- Diastolic Blood Pressure 
 
ECF- Extra Cellular Fluid 
 
ADH- Anti Diuretic Volume 
 
 
 
ABM- Ambulatory Blood Pressure 
 
WCH- White Coat Hypertension 
 
LCAT- Lecithin Cholesterol Acyl Transferase 
 
S.UA- Serum Uric Acid 
 
STD- Standard 
 
IDL- Intermediate Density lipoprotein 
 
CNS-Central Nervous System 
 
ICS- Inter Coastal Space 
 
D/W- Distilled Water 
 
BMI- Body Mass Index 
 
OD- Optical Density 
 
Conc.- Concentration. 
 
 
 
